Protocol I1F-MC-RHCR  (b) 
A 24 -Week Multicenter, Randomized, Double -Blind,  Parallel -Group Study Comparing the 
Efficacy and Safety of  Ixekizumab to Guselkumab in Patients with  Moderate -to-Severe Plaque 
Psoriasis   
 
[STUDY_ID_REMOVED]  
 
Approval Date: 07-Dec-2018 
 
 
 
I1F-MC-RHCR(b) Clinical Protocol Page 1
LY2439821Protoc ol I1F-MC-RHCR (b)
A 24-Week Multicenter, Randomized, Double -Blind , 
Parallel -Group Study  Comparing the Efficacy  and Safety  of 
Ixekizumab to G uselkumab in Patients with 
Moderate -to-Severe Plaque Psoriasis
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_248143] (LY2439821 ), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries .  
Note to Regulatory Authorities:   This document m ay contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the [LOCATION_002], this document is sub ject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Ixekizumab (LY2439821 )
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by L illy on date provided below.
Approval Date: 07-Dec-2018 GMT
I1F-MC-RHCR(b) Clinical Protocol Page 2
LY2439821Table of Contents
Section Page
Protocol  I1F-MC-RHCR(b) A [ADDRESS_301659] ivities....................................................................................................... 12
3. Introduction ...................................................................................................................... 17
3.1. Study  Rationale ............................................................................................................ 17
3.2. Background .................................................................................................................. 17
3.3. Benefit/Risk Assessment .............................................................................................. [ADDRESS_301660] ives and Endpo ints.................................................................................................. 21
5. Study  Design ..................................................................................................................... 23
5.1. Overall Design ............................................................................................................. 23
5.1.1. S creening Period (Period 1) .................................................................................. [ADDRESS_301661] ion Dosing Period (Period 2) ...................................................................... 25
5.1.3. Extensio n Peri od (Peri od 3) .................................................................................. [ADDRESS_301662]-Treatment Follow -Up Peri od (Peri od 4) ....................................................... [ADDRESS_301663] ions.................................................................................................... 34
7. Treatments ........................................................................................................................ 35
7.1. Treatments Administered ............................................................................................. 35
7.1.1. Administrati on of  Ixekizumab, Guselkumab and Placebo ..................................... 36
7.1.2. Observations after Study  Drug Administrati on..................................................... 37
7.1.3. Packaging and Labelling ...................................................................................... 37
7.2. Method of Treatment Assignment ................................................................................ 37
7.3. Screen Failures ............................................................................................................. 38
I1F-MC-RHCR(b) Clinical Protocol Page 3
LY24398217.3.1. Selection and Timing o f Doses ............................................................................. 38
7.4. Blinding ....................................................................................................................... 38
7.5. Dosage Modification .................................................................................................... 39
7.6. Preparati on/Handling/Storage/Accountabilit y............................................................... [ADDRESS_301664] to Follow -Up........................................................................................................ 47
9. Study  Assessments and Procedures ................................................................................... 48
9.1. Efficacy Assessments ................................................................................................... 48
9.1.1. Primary Efficacy  Assessments ............................................................................. 48
[IP_ADDRESS]. Psori asis Area and Severit y Index ................................................................... 48
9.1.2. Major Secondary  Efficacy Assessments ............................................................... 48
[IP_ADDRESS]. Static Physician Global Assessment ................................................................ 48
9.1.3. Other Efficacy  Assessments ................................................................................. 48
[IP_ADDRESS]. Percentage of Body  Surf ace Area ................................................................... 48
[IP_ADDRESS]. Physician’s Global Assessment of Disease Activit y 
Visual Anal og Scale (for Pati ents wi th PsA) ................................................... 49
[IP_ADDRESS]. PGA -F Physician’s Glo bal Assessment of Fingernail 
Psori asis......................................................................................................... 49
9.1.4. Health Outcom e Endpo ints................................................................................... 49
[IP_ADDRESS]. Itch Numeric Rat ing Scale .............................................................................. 49
[IP_ADDRESS]. Skin Pain Visual Analog Scale ....................................................................... 49
[IP_ADDRESS]. Patient’s Gl obal Assessment of Di sease Severit y............................................ 49
[IP_ADDRESS]. Derm atology Life Qualit y Index..................................................................... 49
[IP_ADDRESS]. Patient’s Assessment of Pain Visual Analog Scale (for 
Patients wi th PsA) .......................................................................................... 50
[IP_ADDRESS]. Patient’s Gl obal Assessment of Di sease Act ivity Visual  
Analog Scale (for Pati ents wi th PsA) .............................................................. 50
9.1.5. Appropriateness of Assessments .......................................................................... 50
9.2. Adverse Events ............................................................................................................ 50
9.2.1. Serious Adverse Events ........................................................................................ 51
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301665] ions.......................................... 52
[IP_ADDRESS]. Adverse Events of Special Interest .................................................................. 52
9.2.2. Com plaint Handling ............................................................................................. 53
9.3. Treatment of Overdose .................................................................................................53
9.4. Safety........................................................................................................................... 54
9.4.1. Laboratory  Tests .................................................................................................. 54
9.4.2. Immunogenicit y Assessments .............................................................................. 54
[IP_ADDRESS]. Ixekizumab Serum Concentration ................................................................... [ADDRESS_301666] ing.................................................................55
9.4.5. Columbia -Suicide Severit y Rating Scale .............................................................. 56
9.4.6. Safety Moni toring ................................................................................................ 56
[IP_ADDRESS]. Neutropenia .................................................................................................... 56
[IP_ADDRESS]. Hepati c........................................................................................................... 58
[IP_ADDRESS].1. Hepati c Safet y Data Collection .................................................................58
[IP_ADDRESS]. Hepati tis B Monitoring ................................................................................... [ADDRESS_301667] ical Considerat ions........................................................................ 60
10.3.2. Treatment Group Comparabilit y........................................................................... 61
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 61
[IP_ADDRESS]. Patient Characteri stics.................................................................................... 62
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 62
[IP_ADDRESS]. Treatment Compliance .................................................................................... 62
10.3.3. Efficacy Analyses ................................................................................................ 62
[IP_ADDRESS]. Primary Analyses ........................................................................................... 62
[IP_ADDRESS]. Major Secondary  Analyses ............................................................................. 62
[IP_ADDRESS]. Exploratory  Efficacy  Analyses ........................................................................ 63
10.3.4. Safety Analyses .................................................................................................... 63
[IP_ADDRESS]. Adverse Events ............................................................................................... 63
I1F-MC-RHCR(b) Clinical Protocol Page 5
LY243982110.3.4.2. Clinical Laboratory  Tests ................................................................................ 64
[IP_ADDRESS]. Other Safet y Evaluat ions................................................................................ 64
10.3.5. Evaluat ion of Immunogenicit y............................................................................. 65
10.3.6. Other Analyses ..................................................................................................... 65
[IP_ADDRESS]. Subgroup Analyses ......................................................................................... 65
10.3.7. Interim Analyses .................................................................................................. 65
11. References ........................................................................................................................ 66
12. Appendices ....................................................................................................................... 70
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301668] ives and Endpo ints............................................................................... 21
Table RHCR.7.1. Treatment Regimens ...................................................................................... 35
Table RHCR.7.2. Ixekizumab and Guselkumab Treatment Group Dosing Summary for 
theInduction and Extensio n Peri ods .............................................................. 36
Table RHCR.7.3. Concomitant Medications Permitted/Not Permitted in the Study  and 
Condi tions fo r Use ......................................................................................... 41
Table RHCR.10.1. Primary and Major Secondary  Outcom e Analyses ............................... 63
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301669] of Figures
Figure Page
Figure RHCR.1. Illustrati on of  study  design for clinical protocol RHCR. .................................23
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301670] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 71
Appendix 2. Clinical Laboratory  Tests ............................................................................... 76
Appendix 3. Study  Governance Considerat ions.................................................................. 78
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 83
Appendix 5. Protocol  Amendment I1F -MC-RHCR(b) Summary: A 24 Week 
Multicenter, Randomized, Double Blind, Parallel Group Study  
Com paring the Efficacy and Safet y of Ixekizumab to Guselkumab in 
Patients wi th Moderate to Severe Plaque Psoriasis ......................................... 84
I1F-MC-RHCR(b) Clinical Protocol Page 9
LY24398211.Synopsis
Title of S tudy:
A 24 -week m ulticenter, randomized, doubl e-blind , parallel -group study  com paring the efficacy  
and safet y of ixekizumab to guselkumab in pat ients with moderate -to-severe plaque p soriasis .
Rationale:
In early studies o f biologics targeting the tumornecrosis factor ( TNF )pathway to treat patients 
with chroni c plaque psori asis (hereafter, Ps), significant clinical improvement was ob tained at a 
75% cl earance of skin from baseline (Psoriasis Activit y and Severi ty Index; PASI 75) .  Newer 
biologics targeti ng the interleukin ( IL)-[ADDRESS_301671] clear (at least a 90% improvement from baseline in PASI score ;
PASI 90) or completely clear (a 100 % improvement fro m baseline in PASIscore ;PASI 100) 
skin,and studi es suggest that this improvement is attainable in a high propor tion of  patients 
(Papp et al. 2005; Reich et al. 2005; Leonardi et al. 2008; Menter et al. 2008; Papp et al . 2008; 
Langley  et al . 2014; Griffit hs et al . 2015; Krueger et al. 2015; Lebwohl et al. 2015; Papp et al. 
2015; Blauvelt et al. 2017; Reich et al. 2017) .
As new drugs targeting these pathways c ome to the market, there is a need to directly co mpare
the efficacy  and safet y, as well as rapi[INVESTIGATOR_248144] ,between products to better inform 
derm atologists and pat ients regarding drug selection .
Study  I1F-MC-RHCR (RHCR )isa 24-week study to com pare the efficacy  and safet y, as well as 
rapi[INVESTIGATOR_248144], between ixekizumab and gusel kumab in patients with moderate -to-severe 
Ps.  The primary  efficacy  endpoint of thi s trial isthe pe rcentage of patients reaching 100% 
improve ment from baseline (com plete clearance) in PASI score ,as demonstrated by [CONTACT_47736] 100at 
Week12.
Objective(s)/Endpoints :
Objectives Endpoints
Primary
To assess whether ixekizumab is superior to 
guselkumab at Week 12 in the treatment of patients 
with moderate -to-severe Ps, as measured by [CONTACT_47736] 100The proportion of patients achieving PASI 100 
at Week 12
Major Secondary
To assess whether ixekizumab is superior to 
guselkumab in the treatment of patients with 
moderate -to-severe Psat different time points, as 
measured by:
PASI 75 The proport ion of patients achieving PASI 75 at 
Week 2
PASI 90 The proportion of patients achieving PASI 90at 
Week s 4 and 8
PASI 100 The proportion of patients ac hieving PASI 100 
at Weeks 4, 8 and 24
I1F-MC-RHCR(b) Clinical Protocol Page 10
LY2439821Objectives Endpoints
Static Physician Global Assessment score of 0 
(sPGA [0])The proportion of patients achieving sPGA (0) at 
Week 12
PASI 50 The proport ion of patients achieving PASI 50 at 
Week 1
Abbreviations : PASI = Psoriasis Area and Severity Index; Ps=plaque psoriasis; sPGA = Static Phy sician Global 
Assessment .
Summary of Study Design:
Study RHCR is a mult icenter, randomized, double -blind, parallel -group Phase 4 study  with 
4study  periods in patients with chro nic moderate -to-severe Ps.
Treatment Groups and Duration :
There are 2treatm ent groups in this study.  P atients w ill be rando mized at Week 0 to receive 
either:
(i) I xekizumab :  80 m g subcutaneous ( SC)injection.  At Week 0, 160 mg starting dose 
(two [ADDRESS_301672] ions), fo llowed by 80 m g every  2 weeks (Q2W) from  Weeks 2 
through 12, and then fo llowed by 80 m g every  4 weeks (Q4W) thereafter (i .e., at 
Weeks 16 and 20) .
or
(ii) Guselkumab: [ADDRESS_301673] ion.  At Weeks 0 and 4, 100 mg injection, fo llowed 
by 100 mg every  8 weeks (Q8W) thereafter (i.e., at Weeks 12 and 20).
The study  durati on for the 4 study periodsare: Screening P eriod (Period 1; upto 28days); 
Induct ion Dosing Period
(Period 2; 12 weeks); Extensi onPeriod (Period 3; 12weeks); 
Post-Treatment Follow -Up Peri od (Period 4; at least 12 weeks after the date of patients’ early  
termination visit [ETV] or last regularly scheduled vi sit).
Numbe r of Patients :
Approximately  960 pati ents are planned to be randomized.
Statistical Analysis:
The total sample size for this study  will be 960 patients randomized at a 1:[ADDRESS_301674] ion Dosing Period ( Period2)toixekizumab or guselkumab .
With [ADDRESS_301675] approxima tely 98% power to test the 
superi ority of ixekizumab to guselkumab for PASI 100 at Week 12. The power calculat ion is 
based on the assumpt ion of 35.3% and 23.0% respo nse rate at Week 12 fortheixekizumab and 
guselkumab treatm ent group s, respectively .A 2-sided Fisher ’sexact test at significance level 
0.05is assumed .
For the Induction Dosing Period (Period 2) , 
unless otherwise specified, analyses of efficacy and 
healt h outcom es will  be conducted on the intent -to-treat (ITT) population and safet y analyses 
I1F-MC-RHCR(b) Clinical Protocol Page 11
LY2439821will be conducted on the safet y popul ation.The primary analysis method for treatment 
comparisons of categorical efficacy and health outcome variables will be a 
Cochran -Mantel -Haenszel (CMH ) test stratified by [CONTACT_87843], using the nonresponder 
imputati on(NRI) m ethod .
The primary  analyses for the continuous efficacy and healt h outcome variables will be performed 
using mixed effects model for repeated measures (MMRM) analysis .  The m odel will include 
treatm ent, pooled site, baseline value, visit, treatment -by-visitinteracti on and baseline 
value -by-visit as fixed factors .  A secondary analysis for continuous efficacy and healt h 
outcom es variables will be made using analysis o f covari ance (ANCOVA) adjust ing for pool ed 
siteand baseline value.
Fisher’s exact test will be used for all adverse events (AE), baseline, discont inuat ion, and other 
categori cal safet y data.  Conti nuous laboratory  values will be analyzed by [CONTACT_41418] o f 
covari ance (ANCOVA) with treatment and baseline value in the model .
I1F-MC-RHCR(b) Clinical Protocol Page 12
LY24398212.Schedu le of A ctivities
I1F-MC-RHCR(b) Clinical Protocol Page 16
LY2439821= human immunodeficiency virus; LV = last visit; NRS = numeric rating scale; Patient Assmt of Pain =Patient’s Assessment of Pain ;Patient Global Assmt 
Disease Activity = Patient’s Global Assessment of Disease Activity; PASI = Psoriasis Area an d Severity Index; PatGA = Patient’s global assessment of 
disease severity ;PGA -F = Physician’s Global Assessment of Fingernail Psoriasis ; PK =pharmacokinetics; sPGA =static Physician’s Global Assessment; TB 
= tuberculosis; V =visit;VAS =visual analog scale ; W = week .
aIncludes year of birth, gender, and ethnicity .
bComplete physical at screening (excluding pelvic, rectal, and breast examinations).  Physicals should include symptom -directed physical, as well as an 
examination of heart, lungs, and abdomen, and visual examination of the s kin.
cTo be p erform edifnot do ne in the prior [ADDRESS_301676] positive for latent TB at screening may be re screened following appropriate treatment.  Additionally, patients who do not qualify at baseline 
under Exclusion Criterion [ 34] (active or recent infection) may be re - screened (1 time) .
eSee Table RHCR .7.1. All patients should remain under observation for at least 1 hour after study drug administration to monitor safety at Week 0.
fDesignated Unblinded Site Personnel will be responsible for handling and dispensing of all study drugs(ixekizu mab, guselkumab, and placebo)
.
gAdministered on ly to patients with PsA at the baseline (W0) visit.
hTo be completed only by [CONTACT_248160] (W0) visit.
iPatients who test positive for l atent TB at screening may be re -screened.  QuantiFERON ®may be performed by a Lilly -designated or local laboratory .  See 
Section 9.4.4 for detailed description of QuantiFERON ®-TB Gold .
jFSH test performed for women ≥40 and <[ADDRESS_301677] 12 months to confirm no n-childbearing potential 
(≥40 mIU/mL) .
kAll patients will be tested for HBV at screening .  Patient who meet criteria for HBV monitoring (see Section [IP_ADDRESS] ) will be identified by [CONTACT_248161] .
lTo be performed for females of childbearing potential only.  Additional urine pregnancy testing can be performed at the inves tigator’s decision.  Patients 
determined to be pregnant will be discontinued from treatment and will no longer be administered study drug .
mTo be performed for females of childbearing potential only.  Patients determined to be pregnant will be discontinued from tre atment and will no longer be 
administered study drug .
nTo analyze change from baseline, the immunogenicity sample collected at baseline (W0) will be used.  For any patient w ho experiences a potential systemic 
allergic/hypersensitivity reaction during the study as judged by [CONTACT_093], a sample will also be collected when possi bleto be test edfor immunogenicity 
and PK.  Samples from patients treated with guselkumab will not be analyzed for anti guselkumab antibodies.  These samples will be discarded at the end of 
the study .
I1F-MC-RHCR(b) Clinical Protocol Page 17
LY24398213.Introduction
3.1. Study Rationale
In early studies o f biologicstargeting the tumor necrosis factor (TNF )pathw ay to treat patients 
with chroni c plaque psori asis ( Ps), significant clinical improvement was obtained at a 75% 
clearance of skin fro m baseline ( Psori asis Act ivity and Severit y Index; PASI75).  Newer 
biologics targeti ng the interleukin (IL)-[ADDRESS_301678] clear (at least a 90% improvement from baseline in PASI score ; 
PASI 90) or completely clear (a 100 % improvement fro m baseline in PASIscore ; PASI 100)
skin, and studi es suggest thi s improvement is attainable in a high propor tion of  patients (Papp et 
al. 2005; Reich et al. 2005; Leonardi et al. 2008; Menter et al . 2008; Papp et al. 2008; Langley et 
al. 2014; Griffit hs et al . 2015; Krueger et al. 2015; Lebwohl et al. 2015; Papp et al. 2015; 
Blauvel t et al . 2017; Reich et al. 2017 ).
As new drugs targeting these pathways co me to the market, there is a need to directly co mpare 
the efficacy  and safet y, as well as rapi[INVESTIGATOR_248144] , between products to better inform 
derm atologists and pat ients regarding drug selection .
Study  I1F-MC-RHCR ( RHCR )isa 24-week study to com pare the efficacy  and safet y, as well as 
rapi[INVESTIGATOR_248144], between ixekizumab and guselkumab in patients with moderate -to-severe 
Ps.  The primary  efficacy  endpoint of thi s study isthe percentage of patients reaching 100% 
improve ment from baseline (com plete clearance) in PASI score, as demonstrated by  [CONTACT_47736] 100at 
Week 12.
3.2. Background
Psori asis is a co mmo n, lifelo ng and life -shortening ,chronic inflammatory  skin disease 
manifested by  [CONTACT_248162], thi ck, and scaly plaques.  Plaque p soriasisis the most commo n 
form and has been shown to have a significant impact on the overall healt h of pat ients.  Al ong 
with an associ ation with inflammatory  arthri tis in the form  of psoriatic arthrit is(PsA) , 
Psis 
associ ated wi th increased risk for mult iple co morbid condit ions, including my ocardial  infarct ion 
(MI) and stroke, metabo lic syndrome, diabetes mellitus, chronic renal insufficiency, and liver 
abnorm alities (Yeung et al . 2013 ).  The life span of pat ients with moderate -to-severe Psmay be 
shortened by  [CONTACT_248163] 5 y ears, partl y due to associ ation with com orbidi ties (Gelfand et al. 
2006; Ryan and Kirby  2015 ).
The worl dwide prevalence of Psis 2% to 3% ( Christophers 2001; Internat ional Federati on of  
Psori asis Associations [IFPA] 201 7; Nat ional Psoriasis Foundat ion [NPF] 2018). A lmost
one
-thirdof patients wi th Psin the [LOCATION_002] ( US)suffer from moderate -to-severe disease 
(Dubin et al. 2003 ).  Certain symptoms, such as i tching, can especially  impact the qualit y of life 
and is detrimental to work productivit y and sleep ( Zimo lag et al.2009; Gowda et al. 2010; 
Janowski et al. 2014; Lebw ohl et al . 2014 ).
Early treatm ents for Psobtained 50% to 75% improvement in skin clearance ; however,
expectati onsfor treatm ent g oalsof efficacy are expected to be higher as new and more 
efficacious therapi[INVESTIGATOR_248145] . Recent stu dies of bio logics which block the IL-17or IL -23
I1F -MC -RHCR (b ) C l in ica l  P ro toco l Page  18 
LY2439821 p a t hw a y s ,  b o t h  c e n t r a l  t o  P s p a t h o g e n e s i s (L eon a rd i  e t  a l .2 0 1 2 ;  L a n g l e y  e t  a l .2 0 1 4 ;  S o f e n  e t  a l .
2 0 1 4 ;  Go rdon  e t  a l . 2 0 1 5 ;  G r i f f i t h s  e t  a l .2 0 1 5 ;  K r u e g e r  e t  a l . 2 0 1 5 ;  L e bw o h l  e t  a l .2 0 1 5 ;  P a p p  e t  
a l .2 0 1 5 ) , h a v e  d em on s t r a t ed  s u b s t a n t i a l  e f f i c a cy .Com p l e t e  s k i n  c l e a r a n c e  a n d  im p r o v e d  
l o n g -t e rm  e f f i c a cy  h a v e  i n c r e a s i n g l y  b e c o m e  t h e  d e s i r e d  t r e a tm e n t  o u t c om e s  (G n i a d e c k i  e t  a l .
2 0 1 5 ;  B a r to s e t  a l .2 0 1 6 ) . S om e  s t u d i e s  h a v e  s u g g e s t e d  th a t  i n c r e a s e d l e v e l s  o f  c l e a r an c e  
r e su l t e d  i n  g r e a t e r  im p r o v em e n t  i n  q u a l i t y  o f  l i f e  ( T a k e s h i t a  e t  a l .  2 0 1 4 ;  V i s hw a n a t h a n  e t  a l .  
2 0 1 5 ;  F e l dm a n  e t  a l .  2 0 1 6 ;  F a i r c h i l d  e t  a l .  2 0 1 7 ).
I x e k i z um a b  (LY 2 4 3 9 8 2 1 )  i s  a  h um a n i z e d  imm u n o g l o b u l i n  G ( IgG ) s u b c l a s s 4m o no c l on a l  
a n t ibody (MA b ) d e s i gn ed  and  eng in e e r ed  to  s e l e c t iv e ly  i nh ib i t  IL -1 7A .   I t  b i n d s  w i t h  h i g h  
a f f i n i t y  (< 3 pM )  a n d  s p e c i f i c i t y  to  IL -1 7A ,  a  p r o i n f l amm a t o r y  c y t o k i n e .   N e u t r a l i z a t i o n  o f  
IL -1 7A  b y  i x e k i z um a b  h a s  b e e n  s h ow n  t o  r e d u c e  e x c e s s  k e r a t i n o c y t e  p r o l i f e r a t i o n  a n d  a c t i v a t i o n  
(K r u e g e r e t  a l .  2012 ) .   I x e k i z um a b d o e s  n o t  b i n d  t h e  o t h e r  m em b e r s  o f  t h e  IL - 1 7  f am i l y  ( IL -1 7B ,  
IL -17C ,  IL -17D ,  IL -1 7E ,  o r IL -1 7F ) .
Ix ek i z um a b  h a s  d em on s t r a t e d  e f f i c a c y  a t  b o t h  s h o r t -a n d  l o n g -t e rm  t im e  po in t s ,  w i th  a  f a v o r a b l e  
s a f e t y  p r o f i l e (G r i f f i t h s  e t  a l .  2 0 1 5 ,  G o r d o n  e t  a l .  2 0 1 6 ,  S t r o b e r  e t  a l .  2 0 1 7 ) .   I n  a l l  3p ivo t a l  
P h a s e  3  s t u d i e s  ( t h e  UNCOVER  s t u d i e s ) ,  ix e k i z um a b  w a s  s u p e r i o r  t o  p l a c e b o  w i t h  r e s p e c t  t o  a l l  
p r im a ry  and  m a j o r  s e cond a ry  end po in t s .  In th eUNCOVER  s t u d i e s ,  3 2%  t o  4 2 %  o f  p a t i e n t s  w h o  
r e c e i v e d  t r e a tm e n t  w i t h  i x e k i z um a b  h a d  c o m p l e t e  r e so l u t i o n  (PAS I  100  o r  s t a t i c  P h y s i c i a n  
G l ob a l  A s s e s sm en t  [ sPGA ]s c o r e  o f  0 ;  v e r s u s  [v s .]non e  in  th e  p l a c ebo  g roup )  o f  t h e i r  P s a t  
We ek  12 ;  h i g h  l e v e l s  o f  c l i n i c a l  r e s p o n s e  w e r e  m a i n t a i n e d w i th  con t inu ed  expo su r e  to  
i x e k i z um a b  80  m g  Q4W th rough  We ek  60  w i th  a t  l e a s t  5 0%  o f  p a t i e n t s  m a i n t a i n i n g  o r  a t t a i n i n g  
PAS I  100 (G o r d o n  e t  a l .  2 0 1 6 ).  I n  t h e  UNCOVER -2  a n d  UNCOVER -3  s tud i e s , ix e k i z um a b  h a d 
g r e a t e r  e f f i c a c y  t h a n  e t a n e r c e p t ,a  TNF  i n h i b i t o r  (TNF i ) ; 40 .5 %  o f  p a t i e n t s  t r e a t e d  w i t h  
i x e k i z um a b  8 0  m g  Q2W ,  com p a r ed  w i th  5 .3 %  o f  e t a n e r c e p t -t r e a t e d  p a t i e n t s ,a c h i e v e d  PAS I  1 0 0 
a f t e r  12  w e ek s (G r i f f i t h s  e t  a l .  2015 ,  Go r d o n  e t  a l .  2 0 1 6 ) . I n  a P h a s e  3  h e a d -to -h e a d  s tudy 
( IXORA -S ) ,  i x e k i z um a b d em on s t r a t ed  sup e r i o r i ty  ov e r th e  IL -1 2 / 2 3  a n t a g o n i s t  u s t e k i n um a b  i n  
p a t i en t s  w i th  m od e r a t e -to -s e v e r e  P s a t  W e e k  1 2 ;th i s  t r e n d w a s m a i n t a in ed  th rough  W e ek  52 .  
Th e  m a j o r i ty  (76 .5% )  o f  ix ek i zum ab -t r e a t ed  p a t i e n t s  s u s t a i n e d  a  PAS I  9 0  r e s p o n s e  t h r o u g h  1
y e a r ,  a n d  o v e r  h a l f o f  i x ek i zum ab -t r e a t ed  p a t i en t s  ( 5 2 . 2% )  h a d  c om p l e t e l y  c l e a r  sk in  a t  W e ek  52 .   
Th e  c o r r e s p o n d i n g  r a t e s  f o r  t h e  u s t e k i n um a b -t r e a t ed  p a t i en t s  w e r e  59 .0%  and  35 .5% ,  
r e sp e c t iv e ly .
Gu s e lkum ab i s  a  f u l l y  h um a n  IgG s u b c l a s s 1  l a mbd a  m ono c l on a l  an t ibody  th a t  b ind s  to  th e  p19  
s u b u n i t  o f  IL -2 3 ;  i t i n h i b i t s  t h e  i n t r a c e l l u l a r  a n d  d ow n s t r e am  s i g n a l i n g  o f  IL -2 3 ,  w h i c h  i s  
r equ i r ed  f o r  t e rm i n a l  d i f f e r e n t i a t i o n  a n d  s u r v i v a l  o f  T  h e l p e r  (T h ) 1 7  c e l l s .
I n  2 r e c e n t  Ph a s e  3s tud i e s ,  VOYAGE  1 (B l auv e l t  e t  a l .  2017 )a n d  VOYAGE  2 (R e i ch  e t  a l .  
2 0 1 7 ) , g u s e l k um a b  t r e a tm e n t  ( a dm i n i s t e r e d  a s  a  s i n g l e  1 0 0 -m g  i n j e c t i o n  i n i t i a l ly ,  4  w e ek s  l a t e r  
a n d  s u b s e q u e n t l y  ev e ry  8  w e ek s  [ Q8W ])  r e su l t ed  in  s t a t i s t i c a l l y  s i g n i f i c a n t  im p r o v em e n t s  i n 
e f f i c a c y  com p a r ed  w i th  p l a c ebo a n d  s u p e r i o r i t y  t o  a d a l im um a b ,a  TNF i ,i n  t h e  t r e a tm e n t  o f  
m o d e r a t e -to -s e v e r e  P s (G o r d o n  e t  a l .  2 0 1 8 ) .  I n  t h e  VOYA GE  1  s tudy ,  com p a r ed  w i th  p l a c ebo ,  
s i g n i f i c a n t l y  h i g h e r  p r o p o r t i o n s  o f  p a t i e n t s  t a k i n g  g u s e l k um a b  a c h i e v e d  Inv e s t i g a to r  G l ob a l  
A s s e s sm e n t (IGA ;  c o -p r im a r y  e n d p o i n t )0 / 1  ( 6 . 9%  v s .85 .1% )  and  PAS I  90  ( c o -p r im a r y  
I1F-MC-RHCR(b) Clinical Protocol Page 19
LY2439821endpo int; 2.9% vs .73.3%) at Week 16. In addit ion, the proportions achieving IGA 0 (1.1% vs .
47.7%) and PASI 100 (0.6% vs .37.4% )were significant ly higher for guselkumab vs.placebo at 
Week 16 .Compared with adalimumab ,a higher proporti on of  patients in the guselkumab group 
achieved IGA 0/1 (85.1% vs. 65.9%) and PASI 90 (73.3% vs .49.7%) at Week 16. Significantly 
better responses to guselkumab co mpared with adalimumab were m aintained at Week 24 and at 
Week48;PASI 100 responses in the guselkumab group were alsosignificant ly better than those 
in the adalimumab group at Weeks 24 and 48 .The resul ts of VOYAGE 2 study confirm edthe 
resul ts of VOYAGE 1.  Guselkumab was superior to placebo at the Week 16 co -primary 
endpo ints (IGA 0/1 and PASI 90). Guselkumab was also superior to adalimumab at the Week 16
endpoints (IGA 0/1, PASI 75/90) and at W eek24 (IGA 0, PASI 90 ,and PASI 100) .
Adali mumab is one of the earliest biologics approved for Psand targets the TNF pathway. 
Guselkumab , being one of the most recent bio logics,targets theIL-
23pathway.  As the IL-17/[ADDRESS_301679] ively important in the pathogenesis o f Ps(Leonardi et al.
2012; Langley et al.2014; Sofen et al.2014; Gordon et al. 2015; Griffit hs et al.2015; Krueger et 
al.2015; Lebwohl et al.2015; Papp et al. 2015), the resul ts of the V OYAGE studie s 
(gusel kumab [ IL-
23p19 antagonist ])are not surprising, nor are the resul ts of the UNCOVER -2 
and -3 studi esthat demonstrate dsuperi or efficacy  of ixekizumab (IL-17A antagonist )compared 
to the TNFi etanercept.  These studies help inform dermatologists that newer bio logics have
superi or efficacy co mpared to older biologics targeting theTNF pathway and,thus
,are a good 
choice for treatingpatients who desire nearly clear or com pletely  clear skin .
To date , there is no publicat ion compar ing bio logics for the treatment of Ps that inhibit IL-23
(specifically IL -23p19) vs.those that inhibit IL-17;thusexpectati ons of efficacy  between thes e [ADDRESS_301680] equal, if not 
superi or abili ty compared to guselkumab to achi eve PASI 90 (as shown in the V OYAGE 
studi es). Ixekizumab also demonstrated a high percentage of patients achieving PASI 100, and a 
rapid onset of skin improvement after administration of ixekizumab
(UNCOVER) .  Co mpar ing 
these 2classes of bio logics in a study ,in which both are tested with the same endpo ints and
measured at the same time, will provide important informat ion to clinicians trying to determine 
which drug class is thebest for a given pat ient.  The purpose of this study  is to compare efficacy  
and safet y, as well as rapi[INVESTIGATOR_248144], of 
ixekizumab and guselkumab.
3.3. Benefit/Risk Assessment
Ixekizumab has been demo nstrated to be safe and effect ive for the treatment of patients with 
moderate -to-severe chroni c Psand active PsA .  The risk profile for patients within this study  is 
anticipated to be consistent with the known safet y experience for ixekizumab described in the 
currently approved labeling o f Taltz®(Taltz package insert, 2018) .
More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) ,
and reasonably ant icipated adverse events (AEs) of ixekizumab are found in the Invest igator’s 
Brochure (IB) .Informat ion on AEs expected to be related to the study  drug may be found in 
Secti on 6.2(Development Core Safet y Informat ion) of the IB.  Informat ion on SAEs that are 
expected in the study  popul ation independ ent of drug exposure and that will be assessed by [CONTACT_941] 
I1F-MC-RHCR(b) Clinical Protocol Page 20
LY2439821sponsor in aggregate periodically during the course of the study , may be found in Secti on5
(Effects in Humans ) of the IB .
The known and expected benefits, risks ,and SAEs forgusel kumab are outlined inthe United 
States Package I nsert (USPI )for Tremfya ®(Tremfya USPI [INVESTIGATOR_126880] , 2017; Canada 
Product Monograph , 201 7).
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301681] ives and endpo ints of the study .
Table RHCR .
4.1. Objectives an d Endpoints
Objectives Endpoints
Primary
To assess whether ixekizumab is superior to 
guselkumab at Week 12 in the treatment of patients 
with moderate -to-severe Ps, as measured by [CONTACT_47736] 100The proportion of patients achieving PASI 100
at Week 12
Major Secondary
To assess whether ixekizumab is superior to 
guselkumab in the treatment of patients with 
moderate -to-severe Ps at different time points, as 
measured by:
PASI 75 The proport ion of patients achieving PASI 75 at 
Week 2
PASI 90 The proportion of patients achieving PASI 90at 
Week s 4 and 8
PASI 100 The proportion of patients ac hieving PASI 100 
at Weeks 4, 8 and 24
sPGA [0] The proportion of patients achieving sPGA (0) at 
Week 12
PASI 50 The proport ion of patients achieving PASI 50 at 
Week 1
Exploratory
To assess whether ixekizumab is superior to 
guselkumab in the treatment of patients with 
moderate -to-severe Ps at different time points, as 
measured by:
sPGA score of 0 and 1 (sPGA [0 , 1]) The proportion of patients with a static sPGA 
(0,1) with at least a 2 -point improvement from 
baseline at Weeks 4, 8, 12, 24
Itch NRS:
oResponder oThe proportion of patients achieving the Itch 
NRS Responder definition at Weeks 4, 8, 12, 
and 24(restricted to those patients with Itch 
NRS score ≥4 points at baseline)
oChange f rom baseline oChange f rom baseline in Itch NRS score at 
Weeks 4, 8, 12, and24
oScore of 0 (Itch NRS [0]) oThe proportion of patients achieving Itch NRS 
(0) at Weeks 4, 8, 12, and24(restricted to 
those patients with Itch NRS score >0 at 
baseline)
I1F-MC-RHCR(b) Clinical Protocol Page 22
LY2439821Objectives Endpoints
Skin Pain VAS
oSkin Pain VAS (0) oThe proportion of patients achieving Skin Pain 
VAS (0)at Weeks 4, 8, 12, and24(restricted 
to those patients with Skin Pain VAS score >0 
at baseline)
oChange f rom baseline oChange f rom baseli ne in Skin Pain VAS score
at Weeks 4, 8, 12,and24
DLQI (0,1) The proportion of patients achieving DLQI (0,1) 
at Weeks 2, 4,8, 12, and 24(restricted to those 
patients with DLQI score >1 at baseline)
Abbreviations : DLQI = Dermatology Life Quality Index; NRS = Numeric Rating Scale; PASI = Psoriasis Area and 
Severity  Index; Ps=plaque psoriasis; sPGA = static Physician Global Assessment; VAS = visual analog scale.
I1F-MC-RHCR(b) Clinical Protocol Page 23
LY24398215.Study Design
5.1. Overall Design
Study RHCR is a mult icenter, randomized, double- blind, parallel -group Phase 4study  with 
4study  periods in patients with chro nic moderate -to-severe Ps.
Study  governance considerations are described in detail in Appendix 3 .
Abbreviations:  GUS = guselkumab; IXE = ixekizumab; LV = last visit; Q2W = ever y 2 weeks; Q4W = ever y 4 
weeks; Q8W = every 8 weeks; SC =subcutaneous; R = randomization; V = study visit; W = week.
Figure RHCR .1. Illustration of study design for clinical p rotocol RHCR .
The fo llowing treatm ent groups will be assessed in this study :
Ixekizumab:  80 m g SC injecti on.  At Week 0, 160 mg starting dose (two [ADDRESS_301682] ions), fo llowed by 80 mg Q2W fro m Weeks 2 through 12, and then fo llowed by  
80mg Q4W thereafter (i .e., at Weeks 16 and 20) .
Guselkumab :[ADDRESS_301683] ion.  At Weeks 0 and 4, 100 mg injection, fo llowed by 
100 mg Q8W thereafter (i.e., at Weeks 12 and 20).
The study  will
 consist of 4 peri ods:
Period 1 (Section 5.1.1) :  Screening Period (Visit 1) will assess pat ient eligibilit y and 
occurs approximately  5to 28 days prior to Period 2 (baseline; Week 0 [Visit 2]).
Period 2 (Section 5.1.2
): Induction Dosing Period occurring from Week 0 (baseline ; 
Visit 2) to W eek12(Visit 9).
Period 3 (Section 5.1.3) :  Extension Period occurring afterWeek 12(Visit 9)to 
Week 24 (Visit 12).
Period 4 (Section 5.1.4) : Post-Treatment Follow -Up Period occurr ing from last 
treatm ent peri od V isit 12(Week 24) or ETV ,fora minimum o f 12weeks fo llowing that 
visit.

I1F-MC-RHCR(b) Clinical Protocol Page 24
LY2439821All procedures to be conducted during the study , including timing and sequence (as necessary), 
are indicated in the Schedule o f Activities(Section 2).  Appendix [ADDRESS_301684] -Treatment Follow -Up Peri od (Peri od 4).  F or 
the management of pat ient safet y, all patients should be m onitored through Peri od [ADDRESS_301685] ivities(Secti on 2).
Treatment assignments will remain blinded to investigators, study  site personnel direct ly 
involved in pat ient efficacy and safet y assessments , and pati ents.
Designated Unblinded Site Personnel are responsible for receipt of study  drug shipments, 
dispensing study  drug , administering study  drug ,recording information in the
Study Drug 
Administrati on Log, and con firming treatment assignments.
Unblinded Site Personnel are also responsible for maintaining the blind of the patient (e .g., by 
[CONTACT_3553] a blindfo ld or other appropriate physical barrier means communicated to the sponsor 
for final approval ).Designated Unblinded Site Personnel will not be involved in any clinical 
aspects of the study , including clinical evaluat ions and AE assessments. It is critical that the 
blind is maintained throughout the study  (24weeks).
All treatment groups are descr ibed in Sect ion 7.1, TableRHCR .7.1, and administration of the 
study  drug is described in Sect ion7.1,Table RHCR. 7.2.
Excluded and restricted therapi[INVESTIGATOR_248146] 7.8.
Secti on10.3.7 outlines the information regarding interim analyses, including the primary  
database lock at Week 12.
5.1.1. Screening Period (Period 1)
The durati on of  the Screening Period will be 
5to 28days before the Induction Dosing Period 
(Period 2)and consist sof 1screening visit (Visit 1)to assess patient eligibilit y.  The patient will 
sign the informed consent form (ICF) before any study  assessments, examinat ions, or procedures 
areperform ed.
All inclusio n and exclusion criteria are provided in Sections 6.1and6.2, respectively.  Screening 
procedures (including co mplete me dical  history and dem ographi cs)will be performed ac cording 
to the Schedule of Act ivities(Secti on 2).  At Visit 1, a QuantiFERON ®-TB Gol d test assay  may
be performed by a Lilly -designated or l ocal laboratory (Secti on9.4.4 ).
Patients who test posi tive for l atent tubercul osis(TB)at screening may be re -screene done time
following appropriate treatm ent as described in Secti on 9.4.4.
Additionally, pati ents who do not qualify  at screening under Excl usion Criteria [34]may be 
re-screened (1time) ,as described in Secti
on 7.3with approva l of Lilly Medical Team (clinical 
research scientist [CRS ]/clinical research physician [CRP ]).
I1F-MC-RHCR(b) Clinical Protocol Page 25
LY24398215.1.2. Induction Dosing Period (Period 2 )
The Induct ion Dosing Period (Peri od 2) will be a doubl e-blind treatment period that will occur 
from Week 0 (baseli ne; Visi t 2) to Week 12 (Visi t 9).
At Week 0 (baseline, Visit
2), routine safet y assessments, laboratory  tests, and clinical efficacy 
assessments will be performed on eligible pat ients,according to the Schedule of Act ivities
(Secti on 2).
Patients will  be randomized at a 1:[ADDRESS_301686] -Treatment Follow -Up Peri od (Peri od4; Section 5.1.4 ).
5.1.3. Extension Period (Period 3 )
The Extensio nPeriod(Peri od 3) will be a double -blind treatment period that will occur f rom 
Week 12 (Visit 9) up to Week 24 (Visit 12).
During Period 3, safet y and efficacy  parameters in parti cipat ing patients will continue to be 
evaluated according to the Schedule of Act ivities
(Secti on 2).
Please refer to Section 7.1, 
TableRHCR .7.1, and Table RHCR. 7.2for a full description o f 
treatm ent groups and dosing during Period 3.
Patients who discont inue fromstudy  drug for any  reason during Period [ADDRESS_301687]- Treatment Follow -Up Peri od (Peri od4; Section 5.1.4 ).
5.1.4. Post -Treatment Follow -Up Period (Period 4)
Allpatients receiving at least [ADDRESS_301688] -Treatment Follow -
Up 
Period (Peri od 4) f or a minimum of 12weeks , beginning after thei r last regul arly scheduled visi t 
(or the date of their ETV).  
Requi red study visi ts shoul d occur at 4 weeks (Visit 801) andat 12 weeks (Visit 802) after the 
last regul arly scheduled visit (or the date of the patient’s ETV), except for patients with a 
concurrent infect ion that requires systemic ant i-infective therapy (described in Sect ion9.4.6.1 ).
If, at Vi sit 802, a pati ent’s neutrophil count is ≥1500 cells/ L or greater than or equal to the 
patient’s baseline neutrophil count, the patient’s participati on in the study  will be considered 
complete unless the invest igator determines addit ional fo llow-up m ay be necessary .  An 
additional study  visit (Visit 803) 12 weeks after Visit 802 may be required.  Addit ional visits 
before Visit803 m ay be req uired for appropri ate pati ent management (described in 
Secti on9.4.6.1 ).
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301689] entered Period 4, Ps therapy is allowed, as determine d appropri ate by  [CONTACT_1275]. These allowed Ps therapi [INVESTIGATOR_248147] g the 
doubl e-blind trial.
5.2. Number of Participants
Approximately  1300 participants will be screened to achieve 960 rando mized participants 
(480 randomized participants per treatment group).   Based on experience from the previous 
UNCOVER -1, -2, -3,and IXORA -S trials, a 5% dropout rate is ant icipated .
Patients wi th previ ous bi ologic use can be included in the study  provi dedall inclusio n/excl usion 
criteria, including the washout period(s), as specified in Sections 6.1and6.2of this protocol are 
respected .  Patientswith previous exposure to another IL -[ADDRESS_301690](s) will be limited to 
approximately 15% of  the total  patient popul ation.
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2)for the last patient .
5.4. Scientific Rationale for Study Design
This study  will examine the effect of ixekiz umab vs.that of theactive co mparator ( guselkumab ) 
on patients with moderate -to-severe Ps.
Guselkumab was chosen as the act ivecomparator ,as it:
demonstrates a good safet y profile (Blauvelt et al. 2017; Reich et al. 2017 )
,
is given as SC inject ion, and
represents an important class of drugs for Pstreatment .
During the Induction Dosing Period (Peri od 2), patients rando mized to ixekizumab 
(80mgQ2W ) will be co mpared withpatients randomized to guselkumab (100 mgat Week 0 and 
4).  During the Extensio n Period(Peri od 3), guselkumab 100mgQ 8W (starting atWeek 12 ) and 
ixekizumab [ADDRESS_301691] to measure drug efficacy  in Ps.  
However, data suggested that only higher levels of clinical response (>90% improvement) are 
associ ated wi th norm alizat ion of pat ients’ health -related quali ty of life.  While the se levels of 
clearance are rarely provided by  [CONTACT_248164] , they are m ore consistent ly 
obtained wit h IL-23 antagonists and IL -17 antagonists .  Therefore, in this trial, t he efficacy of 
ixekizumab and guselkumab in treating patients with Pswill be m easured by [CONTACT_248165] 100 
response at Week 12.  Thi s measurement and the Week 12 endpo int are i n alignment with 
efficacy  endpoints for currently  approved Pstherapi [INVESTIGATOR_014], as well as regul atory  guidance (EMA 
2004).
The Extensio nPeriod (Peri od 3) will permit co llection of data for the assessment of longer -term 
safet y and efficacy data ofixekizumab co mpared to guselkumab .
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301692] -Treatment Follow -Up Peri od (Peri od 4) is for safet y monitoring fo llowing the last 
treatm ent peri od and study  visit.
5.5. Justification for Dose
The general approach to dosing ixekizumab in this study  is to use the commercially approved 
dosin g regimen for treatm ent of adults with moderate -to-severe Ps (Taltz USPI [WWW]; Canada 
Product Monograph [WWW]) .
The guselkumab dosing regimen used in this study (100 mgat Weeks 0, 4, 12, and 20 ) is the
approved dose for the treatment of adult s with moderate -to-severe Ps (Tremfya USPI [INVESTIGATOR_248148], 2017; Canada Product Monograph [WWW]) .
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301693] given written 
inform ed consent approved by  [CONTACT_32837] (Lilly ), or i ts designee, and the ethic s 
review board (ERB) governing the site.
Individuals who do not meet the criteria for parti cipati on in this study  (screen failure) m ay be 
re-screened in the fo llowing ci rcumstances:  pati ents who test posi tive for l atent TB at screening 
may be re -screened fo llowing appropriate treatment, as described in Section 9.4.4 .  Addit ionally, 
patients who do not qualify at screening under Exclusio n Cri teria [34] may be re-screened once, 
≥[ADDRESS_301694] sign a new ICF and will be assigned a new ident ificat ion number.
Study  investigator(s) will review patient records and/or patient history  and screening test 
resul ts/measurements to determine if the pati ent meets all inclusio n and exclusio n criteria to 
qualify  for parti cipat ion in the study.  All screening activit ies must be com pleted and reviewed 
before the patient is rando mized.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted .
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all of the fo llowing cri teria:
[1] Patient with chronic plaque psori asis based on a diagnosis for at least 
6months before baseline (Week 0; Visit 2), as determined by [CONTACT_1275] .
[2] Are a candidate for phototherapy  and/or sy stemic therapy .
[3] Have both an sPGA score of ≥3 and a PASI score ≥12 at screening (Visit 1)
and at baseline (Week 0, Visit 2) .
[4] Have ≥10% body  surface area (BSA )involvement at screening (Visit 1) and 
baseline (We ek0, Vi sit 2).
[5] Arepatients 18 years or ol der.
[6] If a male patient, agree to use a reliable method of birth control during the
study .
[7] Female pat ients:
Parti cipants of  child -bearing age or child -bearing potenti al who are sexually 
active who test negat ive for pregnancy must be counseled and agree to use either 
1highly effective m ethod of contraception or [ADDRESS_301695] dose of study  drug.
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301696] ive contraceptive methods are contraindicated or strictly 
declined by  [CONTACT_4676], acceptabl e birth control  methods m ay be considered. These 
may include combinat ion of both of the following methods:
Male or female condo m with spermicide
Cap, diaphragm, or sponge with spermicide
1. Hi ghly effect ive methods of contraception (use 1 form):
a.combined oral contraceptive pi[INVESTIGATOR_81061] -pi[INVESTIGATOR_4382]
b.NuvaRing ®
c.implantable contraceptives
d.injectable contraceptives (such as Depo -Provera ®)
e.intrauterine device (such as Mirena ®and ParaGard ®)
f.contraceptive patch—ONLY women <198 pounds or 90 kg
g.abstinence from sex
h.vasectomy —for men in clinical studies
2. Effect ive methods of contraception (use 2 forms combined)
male condo m with spermicide
female condo m with spermicide
diaphragm  with spermicide
cervical sponge
cervical cap with spermicide
Females who are not of childbearing potential include those who have undergone or who 
have:
female sterilization
hysterectomy
menopause -as confirmed by [CONTACT_248166] -stimulat ing hormone 
(FSH)at baseline.
Müllerian agenesis (Mayer –Roki tansky –Küster–Hauser syndro me [also referred 
to as congenital absence o f the uterus and vagina])
[8] Have given written informed consent approved by [CONTACT_11007], or i ts designee, and 
the Institutional Review Board (IRB)/ERB governing the site.
6.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet anyof the fo llowing cri teria:
[9] Have predominant pattern of pustular, ery throdermic, and/or guttate forms 
of psori asis.
[10] Have a history  of drug -induced psoriasis .
[11] Had a cl inically significant flare of psoriasis during the 12 weeks before
baseline (Week 0, Vi sit 2).
I1F-MC-RHCR(b) Clinical Protocol Page 30
LY2439821Medicat ions/Therapi[INVESTIGATOR_014]
[12] Use of tanning booths for at least 4 weeks before baseline (Week 0, Visit 2) 
and during the study , per invest igator assessment .
[13] Concurrent or recent use of any  biologic agent within the fo llowing periods 
prior to baseline ( Week 0, Visit 2 ):  etanercept <28 day s; infliximab, 
adalimumab, certolizumab pego l, or al efacept <60 days ;golimumab 
<90days; rituximab <12 m onths; secukinumab < 5 months;or any  other 
biologic agent (e.g.,ustekinumab) <5 half -lives.
[14] Have prior use of IL-23p19 antagonist s (e.g. ,guselkumab ,tildra kizumab , 
risankizumab) , or have any condit ion or contraindication as addressed in the 
local labeling for guselkumab that woul d precl ude the pati ent from 
participat ing in this protocol .
[15] Have previously co mpleted or withdrawn fro m this study , parti cipated in 
any other study  with ixekizumab or gusel kumab , have participated in any  
study invest igating IL -23p19 antagonists, or have received tr eatment with 
ixekizumab .
[16] Have previously failed to respond to an IL -[ADDRESS_301697] igator 
assessment.
Vaccinat ions
[17] Have had a live vaccinat ion within 12 weeks o f baseline (Week 0, Visit 2), 
or intend to have a live vaccination during the course of the study  or wi thin 
15weeks of complet ing treat ment in this study , or have participated in a 
vaccine clinical study  within [ADDRESS_301698] igators should 
review the vaccinat ion status of their pat ients and follow the local guidelines 
for adul t vaccinat ion with nonlive vaccines intended to prevent in fectious 
disease before therapy .
(Note:  killed/inactive or subunit vaccines are expected to be safe; however, 
their efficacy with conco mitant ixekizumab and guselkumab treatm ent is 
unknown) .
[18] Have had a vaccinat ion with Bacillus Calmette -Guérin (BCG) within 
12months of baseline (Week 0, Visit 2) or intend to have vaccinat ion with 
BCG during the course of the study  or wi thin 5 half -lifeof com pleting 
treatm ent in this study .
Medical Status and Medical History
[19] Have a known allergy or hy persensitivity to any  biologic therapy  that 
woul d, in the opi[INVESTIGATOR_3078] n of the invest igator, pose an unacceptable risk to the 
patient if parti cipat ing in this study .
[20] Are current ly enrolled in any other clinical study  involving a study  drug or 
any other ty pe of medic al research j udged not to be sci entifically or 
medically co mpat ible with this study.
I1F-MC-RHCR(b) Clinical Protocol Page 31
LY2439821[21] Have had any  major surgery  within 8 weeks of baseline (Week 0, Visit 2) or 
will require majo r surgery  during the study  that, in the opi[INVESTIGATOR_3078] n of the 
investigator in consultation wit h Lilly, would pose an unacceptable risk to 
the pati ent.
[22] Have current or a history  of lymphoproliferat ive disease, or signs or 
symptoms of lymphoproliferat ive disease within 5 years ofbaseline 
(Week 0, Vi sit 2); or have act ive or history of malignant disease within 
5years ofbaseline (Week 0, Visit 2) ,except for basal cell carcino ma, 
squamous cell carcino ma, skin Bowen’s disease or actinic keratoses that 
have been treated with no evidence of r ecurrence in the past [ADDRESS_301699] been removed .
(Note:  patients with history  of malignancy  with no evidence of recur rence 
or active disease wit hin5years ofbaseline may par ticipate in the study ).
[23] Presence of significant uncontrolled cerebro -cardiovascular ( e.g., MI,
arrhy thmias, unstable angina, unstable arterial hypertension, 
moderate -to-severe [[LOCATION_001] Heart Associat ion class III/IV] heart failure, 
or cerebrovascular acci dent), respi [INVESTIGATOR_696] , hepat ic, renal, gastrointest inal, 
endocrine, hematologic, neuro logic or neuropsy chiatri c disorders or 
abnorm al laboratory  values at screening (Visit 1) that, in the opi[INVESTIGATOR_3078] n of the 
investigator, pose an unacceptable risk to the patient i f participat ing in the 
study  or of  interfering with the interpretation of data .
[24] Have had fluid overload, MI, or new onset ischemic heart disease ( e.g., 
unstable angina), unco mpensated heart failure, or in the opi[INVESTIGATOR_3078] n of the 
investigator other serious cardi ac disease within 12 weeks of baseline 
(Week 0; Visi t 2).
[25] Presence of significant uncontrolled neuropsy chiatri c disorder, have recent 
history (within 30 days prior to screening [Visit 1] and any  time between 
screening [Visit 1] and baseline rando mization [ Visit 2]) of a sui cide 
attem pt; or have active suicidal ideat ion with some intent to act with or 
without a specific plan (y es to questi on 4 or 5 on the “Suicidal Ideat ion” 
porti on of  the Columbia -Suicide Severi ty Rating Scal e [C-SSRS ]); or are 
clinically judged by [CONTACT_223963] .
[26] Have evidence of active or non-treated latent TB (refer to Section 9.4.4 for 
details on determining full TB exclusion criteria).
[27] Are posi tive for hum an immunodeficiency virus (HIV) serology  (posi tive 
for HIV antibody ).
[28] Have evidence of or test positive for hepatit is B virus (HBV) by  [CONTACT_140785]:  1) HBV surface ant igen (HBsAg+); OR 2) anti -hepat itis B core 
antibody  (HBcAb+) and are HBV deoxy ribonucleic acid (DNA) posit ive.
I1F-MC-RHCR(b) Clinical Protocol Page 32
LY2439821Note:  Patients who are HBsAg- , and HBcAb+ and HBV DNA negat ive may be 
enrolled in the study .  Pati ents who meet these criteria at screening will be 
ident ified by [CONTACT_248167]9.4.6.3 .
[29] Have evidence of or test positive for hepatit is C virus (HCV).  A posit ive 
test for HCV is defined as:  1) posit ive for hepatit is C ant ibody  and 
2)posit ive via a confirmatory  test f or HCV ( e.g., HCV polymerase chain 
reacti on).
[30] Has any current unstable and/or clinically significant medical condit ion at 
Visit [ADDRESS_301700] igator’s opi[INVESTIGATOR_3078] n coul d interfere wit h parti cipat ion in 
the study .
Infections
[31] Have had a serious infect ion (e.g., pneumo nia, cellulit is, and sepsis), have 
been hospi[INVESTIGATOR_057], or have received intravenous antibiot ics for an infect ion 
within 12 weeks of baseline (Week 0, Visit 2); have had a serious bone or 
joint infect ion within 24 we eks of baseline (Week 0, Visit 2); or have ever 
had an infect ion of an artificial jo int; or are immunocompro mised to an 
extent such that participat ion in the study  woul d pose an unacceptable risk 
to the patient .
[32] Have or have had an infect ion typi[INVESTIGATOR_248149]/or that occurs with increased incidence in an immunocompromised host 
(including, but not limited to, pneumocyst is jiroveci pneumo nia, 
histopl asmosis, or cocci dioidomycosis) or have a known immunodeficiency .
[33] Have or have had a her pes zoster infect ion or any  other clinically apparent 
varicella -zoster vi rus infect ion within 12 weeks of baseline (Week 0, 
Visit 2).
[34] Have had any  other active or recent infect ion within 4 weeks of baseline 
(Week 0, Vi sit 2) that, i n the opi[INVESTIGATOR_3078] n of the inv estigator, would pose an 
unacceptable risk to the patient if participat ing in the study; these pat ients 
may be re -screened (1 time) ≥4 weeks after documented resolut ion of 
symptoms .
Clinical Laboratory  Result s
[35] At screening (Visit 1), have a neutrophil coun t <1500 cells/μL 
(<1.50x10 3/L or <1.50 GI/L) .
[36] At screening (Visit 1), have a lymphocy te count <800 cells/μL 
(<0.80x 103/L or <0.80 GI/L) .
[37] At screening (Visit 1), have a platelet count <100 000 cells/μL 
(<100x 103/L or <100 GI/L) .
I1F-MC-RHCR(b) Clinical Protocol Page 33
LY2439821[38] At screening (Visit 1), h ave aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) >2.5 times (x) the upper limit of normal (ULN) .
(Note:  T he AST and ALT may be repeated once within a week if the init ial 
response exceeds this limit, and the repeat value may  be accept ed if it meets 
this criterion.)
[39] At screening (Visit 1), have alkaline phosphatase (ALP) >3xULN or 
alkaline phosphatase >2.5xULN and total bilirubin >2xULN.
[40] At screening (Visit 1), have a total white blood cell (WBC) count 
<3000 cells/μL (<3.00x 103/L or <3 .00 GI/L).
[41] At screening (Visit 1), have hemoglobin <8.5 g/dL (85.0 g/L) for male 
patients and <8.0 g/d L (80 g/L) for female pat ients.
[42] At screening (Visit 1), have clinical laboratory  test resul ts that are outside 
the norm al reference range for the populati on and are considered clinically  
significa nt, per invest igator assessment.
[43] At screening (Visit 1), have serum  creat inine level >2.0 mg/dL .
(Note:  Laboratory  tests shoul d not be repeated unless there is a technical error or clinical reasons 
to believe a result may  be erroneous .)
Other
[44] Are women who are pregnant, or who are lactating (breast -feeding ).
[45] Have any other condit ion that precludes the patient fro m following and 
completingthe protocol , in the opi[INVESTIGATOR_3078] n of the investigator .
[46] Are invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, 
or sibling, whether bio logical  or legally adopt ed.
[47] Are Lilly  empl oyees or are em ployees of thi rd-party  organizati ons (TPOs) 
involved in the study .
[48] Are unwilling or unable to comply  with the use of a data collect ion device to 
directly record data from the subject .
6.2.1. Rationale for Exclusion of Certain Study Candidates
Exclusio n Cri teria [12] through [16 ] exclude patients who have prior exposure to guselkumab, or 
any other IL-
23p19 antagonist , or ixekizumab (note: see details in Sect ions 6.2and 5.2),or any  
patients who are receiving treatm ent or concomitant medicat ions that could have a negat ive 
impact on the safet y of patients enrolled or confound the results of the study .  Excl usion Criteria 
[17] through [43] exclude patients who would be at a greater safet y risk, including patient s at 
increased risk of infect ive complicat ions or immunosuppression, if administered ixekizumab or 
guselkumab or whose data could confound the results of the study  in the analysis of ixekizumab 
I1F-MC-RHCR(b) Clinical Protocol Page 34
LY2439821and/or patients.  Exclusio n Cri terion [4 4] provi des protecti onto offspring.  Exclusio n Cri teria 
[45], [46], and [47
] reduce the potential bias that may be introduced at the study site.
The m ajority of the exclusion criteria are applied to reduce risks to patients by  [CONTACT_248168], relat ively healthy (aside fro m the disease being studied) patients who are not 
receiving conco mitant therapi [INVESTIGATOR_248150] y and/or confound effects when 
combined wit h the study  drug being studied.
6.3. Lifestyle Restrictions
See inclusio n criteria [6] and [7] in Sect ion6.1for birth control requirements.
I1F-MC-RHCR(b) Clinical Protocol Page 37
LY2439821Syringes shoul d be at room  temperature before injection (refer to the Unblinde d Site Personnel 
Dispensing and Dosing Instructions).
Unblinded Site Personnel will record informat ion in a Study  Drug Administration Log, including 
the date, time, and anatomical locat ion of administration of study  drug (for treatment 
compliance), package number, who administe red the study  drug ,and if applicable, the reason for 
which study  drug was not administered or was not fully administered.   Unblinded Site Personnel 
are al so responsible to make sure pat ients remain blinded to treatment (i.e.,patientsmust not see 
the syringe before, during or after the drug administration) .
7.1.2. Observations after Study Drug Administration
All patients should remain under observat ion for at least [ADDRESS_301701] ion will be supplied by  [CONTACT_248169] h current Good Manufacturing Practice and will be supplied 
with lot numbers, expi[INVESTIGATOR_164075], and certificates of analysis, as applicable .
Ixekizumab and placebo will be supplied as an injectable so lution in 1-mL, single -dose, 
disposable manual sy ringe.  Each sy ringe of  ixekizum ab is designed to deliver 80 mg of 
ixekizumab.  The sy ringes (and contents) containing either ixekizumab or placebo will be visibly  
indist inguishable from each other .  Guselkumab will be supplied as a single -dose 100 mg/mL 
disposable manual prefilled syringe.
Syringes will be supplied in cartons, with the appropriate quantit y of syringes specific to the 
planned dispensing schedule of the study  drug .
Unblinded Site Personnel will be responsible for handling and administering guselkumab , 
ixekizumab ,and placebo to avoid unblinding.
Clinical trial materials will be labeled according to the country ’s regul atory  requi rements.  All 
study  drug s will be stored, inventoried, reconciled, and destroyed according to applicable 
regul ations.
7.2. Method of Treatment Assignment
At Week 0 (Vi sit 2), pati ents who m eet all criteria for enrollment at Visits 1 and 2 will be 
randomized at a 1:1 ratio to double -blind treatm ent groups ( i.e., 80mg ixekizumab or 100mg 
guselkumab ) as determined by a computer- generated random sequence using an interactive 
web-response system (IWRS).  The IWRS will be used to assign blinded study  drug to each 
patient.  The Unblinded Site Personnel at the site will confirm that they  have located the correct 
assigned study  drug package by [CONTACT_45342] a confirmation number found on the package into the 
IWRS as described for Unblinded Site Personnel in the Unblinded Site Personnel Dispensing and 
Dosing Instructions .
Randomization will be st ratified by [CONTACT_248170] .
I1F-MC-RHCR(b) Clinical Protocol Page 38
LY24398217.3. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m aybe 
re-screened . Individuals may be re -screened up to 1time.   
Each time a re-screening is 
perform ed,the individual must sign a new ICF and will be assigned a new identificat ion number.
Individuals may  be re-screened i n the fo llowing ci rcumstances:
Patients who test posi tive for l atent TB at screening and have undergone documented 
subsequent treatment fo r at least 4 weeks (more details in Section 9.4.4 ).
Patients who do not qualify  at screening under exclusio n criteria [34] may  be re-screened 
once ,4 or more weeks after docu
mented resol ution of  symptom s.
Other reasons for re-screening must be discussed, approved and documented by [CONTACT_248171] (CRS/CRP).
7.3.1. Selection and Timing of Doses
Patients will  be assigned to treatm ent and will receive their assigned treatment as outlined in 
Secti ons7.1.[ADDRESS_301702]’s case report form (CRF).   For injections not administered on the scheduled day o fthe 
week from Weeks0 to 1 2, the missed dose should be administered within 3 days of the 
scheduled day; after Week [ADDRESS_301703] ivities(Secti on 2)are com pleted.
Throughout their participation in the study , site personnel  will record informati on in a Study  
Drug Administration Log, including the date, time, and anatomical locat ion of ad ministration o f 
study  drug (for treatment compliance), sy ringe number, who administered the study  drug , and the 
reason if study  drug was not administered or not fully administered.
7.4. Blinding
This is a double -blind study; pat ients and study  site personnel performing assessments of 
outcom es will  be blinded to study drug until all patients have co mpleted the study .  
To preserve 
the blinding of the study , sponsor personnel will not see the randomizat ion table and treatment 
assignments before the study  is unblind ed.  Secti on7.1provides the dosing details pertinent to 
maintenance of the study  blind.  Emergency  unblinding for AEs m ay be perform ed through an 
IWRS which m ay supplement or take the place of emergency codes generated by  a com puter 
drug-labeling system .This option may  beused ONLY if the pat ient’s well -being requires 
knowl edge of the pat ient’s treatment assignment.  All actions resul ting in an unblinding event 
will be recorded and reported by  [CONTACT_8784].
If an invest igator, site personnel performing assessments, or patient is prematurely unblinded, the 
patient m ust be di scont inued fro m the study  drug and should continue in the Post -Treatment 
I1F-MC-RHCR(b) Clinical Protocol Page 39
LY2439821Follow-Up Peri od (Peri od 4) .  In cases for which there are ethical reasons to have the patient 
remain on the study  drug , the invest igator must obtain specific , docum ented approval  from a
Lilly CRS/CRP or representative for the patient to continue in the study .
Processes to maintain blinding during the interim analyses are described in Sect ion10.3.[ADDRESS_301704] igator has the sole responsibilit y for determining if unblinding 
of a pati ent’s treatm ent assignment is warranted for medical management of the event . The 
patient safet y must always be the first considerat ion in making such a determinat ion.  If a 
patient’s treatment assignment is unblinded, Lilly must be notified immediately. If the 
investigator decides that unblinding is warranted, it is the responsib ility of the investi gator to 
prom ptly docum ent the decisio n and rationale and notify Lilly as soon as possible .
7.5. Dosage Modification
Not applicable .
7.6. Preparation/Handling/Storage/Accountability
The invest igator or his/her designee is responsible for the fo llowing:
confirming appropriate temperature condit ions have been maintained during 
transi t for all study  drug received and any discrepancies are reported and resolved 
before use of the study  drug .
ensuring that only participants enro lled in the study  may receive study  drug and 
only authori zed si te staff may supply  andadminister study  drug .  All study  drug s 
must be stored in a secure, environmentally controlled, and mo nitored (m anual  or 
autom ated) area in accordance wit h the l abeled stor age condi tions wi th access 
limited to the investigator and authorized site staff.
the invest igator, inst itution, or the head of the medical inst itution (where 
applicable) is responsible for study  drug accountabilit y, reconciliat ion, and record 
maintenance (such as receipt, reconciliat ion and final disposit ion records) .
the study  drug shoul d be stored at 2°C to 8°C (36°F to 46°F) in its original carton to 
protect from light.  Study  drug shoul d not be frozen.  Sites will be required to monitor 
temperature of the on -site storage condit ions of the study  drug .
Details for the requirements for dispensing ixekizumab, guselkumab ,and placebo sy ringes will 
be provid ed to the Unblinded Site Personnel in the Unblinded Site Personnel Dispe nsing and 
Dosing Instructions.
7.7. Treatment Compliance
Every  attem pt will be m ade to sel ect pati ents who have the abilit y to understand and comply with 
instructi ons.  To ensure high treatment compliance, the invest igator is responsible for discussing 
requi rements of the tri alwith the pati ent before randomizat ion.
Throughout their participation in the treatment periods (Induction Dosing and Extensio n
Periods), trained unblinded site personnel will record inform ation in a Study  Drug 
I1F-MC-RHCR(b) Clinical Protocol Page 40
LY2439821Administrati on Log, including the date, time, and anatomical locat ion of administration of study  
drug, syringe number, who administered the study  drug , the reason i f the study  drug was not 
administered or not fully administered ,and the count of empty study  drug packaging.   The time 
and day  of each study  drug administration (and other items included in the above paragraph) 
must be recorded into the electronic case report form (eCRF) by [CONTACT_8786].
7.8. Concomitant Therapy
All conco mitant m edicat ion taken during th e study must be recorded on the Concomitant 
Medicat ion CRF at the study  visit s indicated in the Schedule of Activit ies(Secti on 2).  Treatment 
withconco mitant Pstherapi [INVESTIGATOR_248151] n 
and exclusio n criteria (Secti ons6.1and 6.2,respectively) and as described in the paragraphs 
below .  Pati ents taking permitted medicat ions need to be documented to be in stable control.  
After tri al enrollment, si gnifican t dose escal ation of  a concomi tant medicat ion shoul d be 
discussed wi th Lilly  medical  before all owing patient to receive study  drug .
Table RHCR. 7.3summarizes concomitant medicatio nsthat are and are not permitted and their 
condi tions for use during the study .
I1F-MC-RHCR(b) Clinical Protocol Page 41
LY2439821Table RHCR. 7.3. Concomitant Medications Permitted/Not Permitted in the Study and Conditions for Use
Drug Class Permitted/Not 
Permitted
During the 
TrialConditions for Use
Bath oils and oatmeal bath preparations Permitted Not to be used within 12 hours of a study visit.
NSAIDs, acetaminophen, or aspi[INVESTIGATOR_248152].
Shampoos Permitted May not contain >3% salicylic acid, corticosteroids, coal tar, or vitamin D3 
analogues.
Not to be used within 12 hours of a study visit.
Topi[INVESTIGATOR_213118]/emollients and other 
non-prescription topi[INVESTIGATOR_248153], >3% salicylic acid, alpha -or beta -hydroxy l acids, 
corticosteroids, or vitamin D3 analogues.  Not to be used within 12 hours of a study 
visit.
Topi[INVESTIGATOR_2855] s teroids
mild (such as hydrocortisone) are permitted Permitted Permitted for use limited to the face, axilla, groin ,and/or genitalia, as needed.  These 
topi[INVESTIGATOR_248154] 24 hours before study 
visits requiring sPGA and PASI measures.  More widespread use on large surfaces is 
not permitted.
strong (such as mometasone) ,very strong 
(Betamethasone) a, and Halogenated steroids
(clobetesone) are not permittedNot permitted
Biologic agents other than study drug as part of this 
protocol Not Permitted Washout periods before baseline (Week 0, Visit 2 ); at least [ADDRESS_301705] never received ixekizumab or IL-23p19 antagonists ;or participated in any 
study investigating IL-23p19 antagonists .  Patient with previous exposure to another 
IL-[ADDRESS_301706](s) will be limited to approximately 15% of the total patient 
populatio n.
Natalizumab or other agents targeting α [ADDRESS_301707] never received.
Phototherapy (including either oral and topi[INVESTIGATOR_57958], UVB, or self -treatment with tanning 
beds or therapeutic sunbathing)Not permitted Must not have received within 4 weeks of baseline (Week 0, Visit 2) .
I1F-MC-RHCR(b) Clinical Protocol Page 42
LY2439821Concomitant Medications Permitted/Not Permitted in the Study and Conditions for Use
Abbreviations:  CRS/CRP = clinical research scientist/clinical research physician; IL = interleukin; MTX = methotrexate; NSAID = nonsteroidal 
anti-inflammatory drug; PASI = Psoriasis Area and Severity Index; PUVA = psoralen and ultraviolet A; sPGA = static Physician Globa l Assessment; 
UVB =ultraviolet B.
aMason et al. 2002.Drug Class Permitted/Not 
PermittedConditions for Use
Systemic nonbiologic psoriasis therapy  (e.g., oral 
psoralens and ultraviolet A light therapy, cyclosporine, 
corticosteroids, MTX, oral retinoids, mycophenolate 
mofetil, thioguanine, hydroxyurea, sirolimus, 
azathioprine, fumaric acid derivatives, apremilast, and
1, 25 dihydroxy vitamin D3 and analogues)Not permitted Must not have received within 4 weeks of baseline (Week 0, Visit 2).
Vaccine, Bacillus Calmette -Guérin Not permitted Must not have received within 12 months of baseline (Week 0, Visit 2).
Should not receive within [ADDRESS_301708] received within 12 weeks of baseline (Week 0, Visit 2).
Should not receive within 15 weeks of completed treatment in this study.
Vaccines, nonlive seasonal and/or emergency Permitted with 
conditio nsKilled/inactive or subunit vacci nes are expected to be safe; however, their efficacy 
with concomitant ixekizumab and guselkumab treatment sis unknown . Check with
Lilly  Medical Team (CRS/CRP) before administration .
I1F-MC-RHCR(b) Clinical Protocol Page 43
LY2439821Addit ional drugs are to be avo ided during the study unless required to treat an AE or for the 
treatm ent of an ongoing medical problem.  If the need for concomitant medication arise s, the 
investigator should base decisio ns on the patient and clinical factors.  Any  addi tional medicat ion
(including the limited use of therapeut ic agents which, if used under treatment regimens other 
than for treating an AE or for appropriate medical mana gement, might be considered Ps 
therapi [INVESTIGATOR_014])whether prescript ion or over -the-counter, used at baseline (Week 0, Visit 2) and/or 
during the course of the study ,must be docum ented wi th the start and stop dates on the 
Concomitant Medications CRF .
Patients will  maintain thei r usual medicat ion regimen for other concomitant diseases throughout 
the study  unless those m edicat ions are specifically  excluded in the protocol .  Pati ents taking 
concomitant medicat ions should be on stabl e doses at the time of baseline (Week 0, Visit 2) and 
shoul d remain at a stabl e dose throughout the study , unless changes need to be made for an AE 
or for appropriate medical management.  Other medicat ions may be allowed if approved by  [CONTACT_248172] d esignee .
Patients shoul d be instructed to consult the invest igator or other appropriate study personnel at 
the site before taking any new medicat ions or supplements.  Any changes in medicat ions not 
addressed above should be discussed by [CONTACT_248173] .
7.9. Treatment after the End of the Study
7.9.1. Treatment after Study Completion
Study  drug will not be made available after conclusion of the study  to pati ents.
7.9.2. Special Treatment Considerations
Patients will  be screened for eligibilit y in the study as described in Sections6.1and 6.2and will 
be informed of the study -specific restrict ions and requirements of the study .  Pati ents who are not 
willing to comply wit h the study  restricti ons and requi rements of the study  will not be eli gible 
for enrollment.
All biological agents carry  the risk of systemic allergic/hypersensit ivity reacti ons.  Clinical  
manifestation s of these reacti ons m ay include, but are not limit ed to:
skin rash
pruri tus (i tching)
urticaria (hives)
angioedema ( e.g., swelling of the lips and/or tongue)
anaphylactic reaction
Sometimes these react ions can be life -threatening.  Proteins may  also cause redness, i tching, 
swelling, or pain locally at the inject ion site.  Therefore, all pat ients should be closely mo nitored 
for signs or symptoms that could result from such reactions, be educated on the signs or 
symptoms of these ty pes of  react ions, and be i nstructed to contact [CONTACT_248174].  If a patient experiences an acute 
I1F-MC-RHCR(b) Clinical Protocol Page 44
LY2439821allergic/hypersensit ivity react ion after an inject ion of study  drug , he or she should be managed 
appropriately and given instruction to rec eive relevant supportive care.
Addit ionally , for an event j udged by  [CONTACT_140800] a potential systemic 
allergic/hypersensit ivity react ion, a blood sample should be drawn as soon as possible.  These 
samples may  be teste d for anti -drug antibodies (ADAs), other laboratory  tests needed to 
elucidate the cause of the allergic/hypersensit ivity reacti on, and/or ixekizumab serum 
concentration.  These results will not be provided to the investigator for patient care decisio ns 
butare intended to assist the sponsor in accurately characterizing the reaction.
For pati ents who experience a potential allergic/hypersensit ivity react ion, consideration for any  
prem edicat ion for future inject ions will be agreed upon between the investigato r and sponsor 
and/or its designee.  Examples o f potenti al allergi c/hypersensit ivity react ions that might merit 
prem edicat ion include mild -to-moderate skin rashes, mild -to-moderate generalized pruritus 
and/or urti caria, and mild -to-moderate inject ion site r eactions ( e.g., injection -site ery thema, 
inject ion-site pruri tus).  Pati ents who develop clinically significant sy stemic 
allergic/hypersensit ivity react ions following administration of study  drug who do not r espond to 
symptom atic medicat ion,or have a reac tion that result sin clinical sequelae ( e.g., 
hospi [INVESTIGATOR_28689]),shoul d be discont inued fro m study drug and not receive further doses of study  
drug, with or wi thout prem edicati on (Secti on8.1).  Medi cations considered appropriate for 
prem edicat ion include (but are not restricted to) acetamin ophen/paracetam ol up to 1000 mgand 
antihistamines ( e.g., oral diphenhydramine, 50 mg) give n [ADDRESS_301709] ion.  Patients may self -premedicate at home before administration of study  drug , as di rected 
by [CONTACT_093].  All such premedicat ions will be recorded as concomitant therapy .  
Corti costeroi ds are not permitte d as agents for premedicat ion.
I1F-MC-RHCR(b) Clinical Protocol Page 45
LY24398218.Discontinuation Criteria
8.1. Discontinuation from Study drug
8.1.1. Permanent Discontinuation from Study drug
Possible r easons leading to permanent discontinuatio n of study  drug :
Subject Decision
othe patientrequests to discont inue study  drug .
Discontinuation due to a hepatic event or liver test abnormality.
oPatients who are discont inued fro m study  drug due to a hepatic event or liver test 
abnorm ality should have addi tional hepatic safet y data collected via CRF .
Discontinuati on of  the study  drug for abnorm al liver tests should be considered by [CONTACT_32845] a patientmeets one of the fo llowing condit ions after consultation 
with the Lilly designated medical mo nitor:
ALT or AST >[ADDRESS_301710]
ALT or AST >[ADDRESS_301711] for m ore than 2 weeks
ALT or AST >[ADDRESS_301712] and total bilirubin level (TBL) >2x ULN or 
internat ional norm alized rati o (INR)>1.5
ALT or AST >[ADDRESS_301713] wi th the appearance of fat igue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
ALP >3x ULN
ALP >2.5xULN and TBL >[ADDRESS_301714]
ALP >2.5xULN wi th the appearance of fat igue, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
In addit ion, patients will be discont inued fro m the study  drug in thefollowing circumstances :
Neutrophil (segmented) counts (see safet y monitoring for neutropeni a Sect ion9.4.6.1 ):
<500 cells/ L
≥500 and <1000 cells/ L (based on [ADDRESS_301715] results; the second test performed 
within 1 week fro m knowledge of the init ial result)
≥1000 and <1500 cells/ L (based on [ADDRESS_301716] resul ts as specified in Section [IP_ADDRESS] ) 
AND an infect ion that i s not fully  resolved
Total  WBC count <2000 cells/ L
Lymphocy te count <200 cells/μL
Platelet coun t <50,000 cells/μL
The patient experiences a severe AE, an SAE, or a clinically significant change in a 
laboratory  value occurs that in the opi[INVESTIGATOR_871], merits the discontinuation 
I1F-MC-RHCR(b) Clinical Protocol Page 46
LY2439821of the study  drug and appropriate measures bein g taken.  In this case, Lilly  or its designee 
is to be notified immediately via email and the event is to be documented .
Clinically significant sy stemic hypersensit ivity reacti on following SC administration of 
study  drug that does not respond to symptomat ic medicat ion or resul ts in clinical 
sequelae
The patient beco mes pregnant
The patient develops a malignancy (Note:  patients may  be allowed to continue if they  
develop no more than 2 non -melanoma skin cancers during the study )
if the pat ient develops active suicidal ideat ion with som e intent to act with or without a 
specific plan (y es to questi on 4 or 5 on the “Suicidal Ideation” portion of the C -SSRS),
-OR-
if the pat ient develops suicide -related behavior s as recorded on the C -SSRS,
then it is recommended that the patient be assessed by a psychiatrist or appropriately 
trained professio nal to assist in deciding whether the pat ient is to be discontinued from 
the study .
Patients discont inuing fro m the study  drug prematurely for any reason should co mplete AEand 
other fo llow-up procedures per Section 2(Schedule of Act ivities), Section 9.2(Adverse Events) ,
and Sect ion 9.4(Safety) of this protocol .
8.1.2. Discontinuation of Inadvertently Enrol led Patients
The cri teria for enrollment m ust be fo llowed explici tly.
If the sponsor or invest igator ident ify a pat ientwho did not meet enrollment criteria and was 
inadvertent ly enro lled, then the patient should be discontinued fro m study  treatm entunless there 
are extenuat ing circumstances that make it medically n ecessary  for the pati ent to conti nue on 
study  drug .  If the invest igator and the sponsor CRP agree it is medically appropriate to continue, 
the invest igator must obtain documented approval fro m the sponsor CRP to allow the 
inadvertent ly enro lled patienttoconti nue in the study  with or wi thout treatm ent wi th study  drug . 
Safety follow-up is as outlined in Sect ion 2(Schedule of Act ivities), Section 9.2(Adverse 
Events), and Section 9.4(Safet y) of the protocol .
8.2. Discontinuation from the Study
Patients will be discont inued in the fo llowing ci rcumstances:
enrollment in any other clinical study  involving an study  drug or enrollment in 
any other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
participat ion in the study needs to be stopped fo r medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and good clinical 
practi ce 
I1F-MC-RHCR(b) Clinical Protocol Page 47
LY2439821investi gator decisio n
the invest igator deci des that the patientshould be discontinued fromthe 
study
if the patientfor any reason, requi res treatm ent wi th another therapeuti c 
agent that has been demonstrated to be effect ive for the treatm ent of the 
study  indicat ion, discont inuat ion from the study  occurs before introduction 
of the new agent
subject decisio n
the patient requests to be withdrawn fro m the study
Patients discont inuing fro m the study  prem aturely for any  reason shoul d com plete AE
and other safet y follow-up per Secti on2(Schedule of Act ivities), Section 9.2(Adverse 
Events) ,and Section 9.4(Safet y) of this protocol .
8.3. Lost to Follow -Up
A pat ient will be cons idered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_4145].  Site personnel are expected to make 
diligent attempts to contact [CONTACT_248175]/relat ives who fail to return for a scheduled 
visit or were otherwise unable to be foll owed up by  [CONTACT_4179].
Lilly personnel will not be invo lved in any attempts to collect vital status informat ion.
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301717] ivities, wi th the study  procedures and their timing (including 
tolerance limit s for timing).   All study  assessments except for the C -SSRS, Self -Harm , and 
Self-Harm Fo llow-Up will be completed el ectroni cally .
Appendix [ADDRESS_301718] results.  Certain samples may 
be re tained for a l onger peri od, if necessary , to comply  with applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1. Efficacy Assessments
9.1.1. Prima ry Efficacy Assessments
The primary  efficacy  endpoint i s PASI 100 response at Week 12 (Visit 9).
[IP_ADDRESS]. Psorias is Area and Severity Index
The PASI is an accepted primary efficacy  measurement for thi s phase of development of Ps
treatm ents (EMA 2004).  The PASI combines assessments of the extent of body -surface 
involvement in 4 anatomical regio ns (head, trunk, arms, and legs) and the severit y of 
desquamat ion (scaling), ery thema, and plaque induration/infiltration (thickness) in each region, 
yielding an overall score from [ADDRESS_301719] severe disease (Fredriksson and 
Pettersson 1978).  The PASI has been the most frequent ly used endpo int and m easure of Ps
severit y in clinical trials (EMA 2004; Menter et al. 2008).  A clinically meaningful response is a 
PASI 75, which represents at least a 75% decrease (improvement) fro m the baseline PASI score.  
Higher l evels of clearance (PASI 90), as well as complete resolution of Ps(PASI 100), have 
beco me addit ional endpoints because o f the increasing recognit ion of the associat ion of highe r 
clearance with greater heal th-related quali ty of life (Pui g 2015).
9.1.2. Major Secondary Efficacy Assessments
[IP_ADDRESS]. Static Physician Global Assessment
The sPGA is the physician’s determination o f the pati ent’s Pslesions overall  at a given t ime 
point.  The s PGA is recommended as a n endpo int to assess efficacy in the treatment of Ps(EMA 
2004).  Overall, lesions are categorized by [CONTACT_248176], ery thema, and scaling.  
For the analysis o f responses, the patient’s Psis assessed as clear (0), minimal (1), mild (2), 
moderate (3), severe (4), or very  severe (5).
9.1.3. Other Efficacy Assessments
[IP_ADDRESS]. Percentage of Body Surface Area
The invest igator will evaluate the percentage invo lvement of Pson each patient’s BSA on a 
continuous scale from 0% (no invo lvement) to 100% (full invo lvement), in which 
I1F-MC-RHCR(b) Clinical Protocol Page 49
LY24398211%corresponds to the size of the patient’s hand (including the palm, fingers, and thumb) 
(Thom as and Finlay  2007).
[IP_ADDRESS]. Physician’s Global Assessment of Disease Activity Visual Analog Scale
(for Patients with PsA)
The i nvestigator will be asked to give an overall assessment of the severit y of the pati ent’s 
current PsA activit y using a 100 -mm horizontal  visual analog scale (VAS ), where [ADDRESS_301720] or m edically qualified physician. The same assessor should 
preferably perform the Physic ian’s Gl obal Ass essment of Disease Act ivity VAS f or a given 
patient to minimize inter -observer var iation.
[IP_ADDRESS]. PGA -FPhysician’s Global Assessment of Fingernail Psoriasis
The Physician’s Global Assessment of Fingernail Psoriasis (PGA -F), was devel oped f or 
clinicians to evaluate the severit y of fingernail abnorm alities in pat ients with nail psori asis.  The 
scale assesses the nail bed and nail matrix signs o f disease on a 0 to 4 scale (0 -clear, 
1 -minimal, 2 -mild, 3 -moderate, 4 -severe) .
9.1.4. Health Outcome Endpoints
[IP_ADDRESS]. Itch Numeric Rating Scale
The Itch NRS is a patient -administered single -item 11 -point horizontal  scale anchored at 0 and 
10, wi th 0 represent ing “no itch” and 10 represent ing “worst itch imaginable.”  Patients indicate 
their overall  severi ty of itching from  Psby [CONTACT_248177] 24 hours.
[IP_ADDRESS]. Skin Pain Visual Analog Scale
The Skin Pain VAS is a patient -administered scale designed to measure skin pain fro m Psusing 
a 100 -mm horizontal  VAS.  Overall severit y of a pati ent’s skin pain fro m Psat the present time 
is indicated by  [CONTACT_1299] a single m ark on the hori zontal  scale (0 = no skin pain; 100 =severe skin 
pain).
[IP_ADDRESS]. Patient’s Global Assessment of Disease Severity
The Patient’s GlobalAssessment of Disease Severi tyis a pat ient-administered, single -item scale 
on which patients are asked to rank, by  [CONTACT_569] a number on a 0 to 5 NRS, the severit y of their
Ps“today ” from 0 (cl ear), no Ps; to 5 (severe).
[IP_ADDRESS]. Dermatology Life Quality Index
The Derm atology Life Qualit y Index (DLQI )is a simple, patient -administered, [ADDRESS_301721] ionnaire that covers 6 domains:  symptoms and feelings, daily 
activit ies, leisure, work and school, personal re lationships, and treatment.  Response categories 
include “not at all,” “a little,” “a lot,” and “very much,” with corresponding scores of 0, 1, 2, and 
3, respecti vely, and “not relevant” responses scored as “0. ”  Totals range fro m 0 to 30 (less to 
more impairment) , a DLQI score of [ADDRESS_301722] on patients’ life .
I1F-MC-RHCR(b) Clinical Protocol Page 50
LY24398219.1.4.5. Patient’s Assessment of Pain Visual Analog Scale (for Patients with PsA)
The patient will be asked to assess his or her current level o f joint pain by [CONTACT_112536] a vert ical tick 
on a [ADDRESS_301723] possible jo int pain. Results will be expressed in millimeters measured between 
the left end of the scale and the crossing po int of the vertical line of the tick; this procedure is 
applicable for all VAS used in the tr ial.
[IP_ADDRESS]. Patient’s Global Assessment of Disease Activity Visual Analog Scale (for 
Patients with PsA)
The patient’s overall assessmen t of his or her PsA activit y will be recorded using the 100- mm 
horizontal  VAS where the l eft end represents no disease act ivity and the ri ght end represents 
extrem ely active disea se activit y.
9.1.5. Appropriateness of Assessments
All o f the clinical and safet y assessments/measures included in the primary  and maj or secondary  
objectives in this study  are standard, widely used, and generally  recognized as rel iable, accurate, 
and relevant.
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of patientswho have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of patients during the study.
Invest igators must document their review of each laboratory  safety  report .
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the study  drug or the 
study , or that caused the patientto discont inue the study  drugbefore complet ing the study.  The 
patientshoul d be f ollowed unt il the event resolves, stabilizes with appropriate diagnostic 
evaluat ion, or is reasonably  explained.  The frequency of follow -up evaluat ions of the AE is left 
to the di scret ion of the inves tigator .
After the ICF is signed, study  site personnel will record via eCRF the occurrence and nature of 
each patient ’s preexist ing condit ions, including clinically significant signs and symptoms of the 
disease under treatment in the study .  In addit ion, site personnel  will record any  change in the 
condi tion(s) and any  new condi tions as AEs . Investi gators shoul d record thei r assessment of the 
potenti al relatedness of each AE to protocol procedure, study drug , via eCRF .
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study drug , study  device, or a study  procedure, taking into accoun t the 
disease, concomitant treatment, or pathologies .
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the study  
drug, study  device ,and/or study  procedure and the AE .
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301724] igator answers ye s/no when m aking this assessment .
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient ’s study  drug is discont inued as a result of an AE, study  site personnel  must report this 
to Lilly  or its desi gnee via eCRF , clarifying if possible, the circumstances leading to 
discontinuat ions of treatment .
Study site personnel  must al ert Lilly or i ts desi gnee wi thin [ADDRESS_301725] igator 
unblinding a patient’s treatment group assi gnment for any  reason.
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or hospi[INVESTIGATOR_18543],but may  jeopardi ze the pati ent or may  requi re 
intervent ion to prevent one of the other outcomes listed in the definit ion above.   
Examples of such medical events include allergi c bronchospasm requiring 
intensive treatm ent in an emergency  room  or at home, blood dyscrasias or 
convulsio ns that do not result in inpatient hospi[INVESTIGATOR_059], or the development of 
drug dependency  or drug abuse.
All AEs occurring after signing the ICF are recorded in the eCRF and assessed for serious 
criteria.  The SAE reporting to the sponsor begins after the patient has signed the ICF and has 
received study  drug .  However, if an SAE occurs after signing the ICF, but prior to receiving 
study  drug , the SAE shoul d be reported to the sponsor per SAE reporting requirements and 
timelines (see Sect ion 9.2) if it is considered reasonably possibly related to study procedure .
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within [ADDRESS_301726] addi tional data collecte d using the 
eCRF .
Pregnancy ( during maternal or paternal exposure to study  drug ) does not m eet the definit ion of 
an AE.  However, to fulfill regulatory  requi rements any pregnancy  should be reported following 
the SAE process to collect data on the outcome for both mother and fetus .
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301727] 
discontinued and/or completed the study  (the patientdisposit ion CRF has been comp leted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  drug or study  parti cipat ion, the investigator must prompt ly notify Lilly .
Data on occurr ence of SAEs up to and including the patient’s last study  visit will be co llected, 
regardl ess of the invest igator’s opi[INVESTIGATOR_3078] n of causat ion, in the clinical data collection database and 
the pharmacovigilance system at the sponsor.
Inform ation on SAEs expected in the study  popul ation independent of drug exposure and that 
will be assessed by [CONTACT_248178] .
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are seri ous events that are not listed 
in the IB and that the investigator ident ifies as related to study drug or procedure.  [LOCATION_002]
21 CFR 312.32 and European Unio n Clinical Trial Directive 2001/20/EC and the associated 
detailed guidances or nati onal regulatory  requi rements in parti cipat ing countries require the 
reporting of S[LOCATION_003]Rs .  Lilly has procedures that will be fo llowed f or the ident ificat ion, recordi ng 
and expedited reporting of S[LOCATION_003]Rs that are consistent with g lobal regulat ions and the associated 
detailed guidances .
[IP_ADDRESS]. Adverse Events of Special Interest
The fo llowing adverse events of special interest (AESIs) will be used to determine the safet y and 
tolerabilit y of ixekizumab over the range of doses selected for this clinical study .
Adverse events of special int erest sfor ixekizumab are the following :
cytopeni as (leukopenia, neutropenia, and thrombocy topeni a)
liver funct ion test changes/enzyme elevat ions (ALT, AST, bilirubin, and ALP)
infect ions
inject ion-site reacti ons
allergic reactions/hypersensit ivities
cereb ro-cardiovascular events
malignancies
inflammatory  bowel  disease (IBD)
depressio n 
Sites will provide details on AEs as instructed on the eCRF.  Invest igators will also educate 
patients and/or caregivers about the symptoms of systemic allergic/hypersensit ivity react ions and 
will provide instructions on the management and reporting of these reactions.  Blood samples 
will be co llected as soon as possible for any pat ient who experiences an AE of a potential 
I1F-MC-RHCR(b) Clinical Protocol Page 53
LY2439821systemic allergic/hypersensit ivity react ion during th e study  as judged by [CONTACT_3170].  These 
samples may  be tested for ADAs, other laboratory tests needed to elucidate the cause of the 
allergic/hypersensit ivity react ion, and/or ixekizumab serum concentration.
Data on preferred terms associated with cer ebro-cardi ovascular events (defined as death, cardiac 
ischemic event including MI and hospi[INVESTIGATOR_248155], hospi[INVESTIGATOR_140756], serious arrhy thmia, resuscitated sudden death, cardiogenic shock, coronary  
revascularization proce dure, stroke/transient ischemic attack, peripheral revascularization 
procedure, peripheral arterial event, and hospi[INVESTIGATOR_140757]) will be collected, and 
these events and any deaths will be adjudicated by [CONTACT_248179] (CEC) 
made up of a chairperson, [ADDRESS_301728]. 
Data on suspected IBD, as identified by  [CONTACT_140817]’s disease, will be co llected and the events will be adjudicated by [CONTACT_248180].
The rol e of the external CECs is to adjudicate defined clinical events in a blinded, consistent, and 
unbiased manner throughout the course of a study .  The purpose of the CEC for adjudicat ion of 
cerebro -cardio vascular events and the CEC for adjudi cation of suspected IBD events is to ensure 
that all reported events are evaluated uniformly by a single group.
9.2.2. Complaint Handling
Lilly co llects product complaints on study  drug s and drug delivery  systems used in clinical 
studi es in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to facilitate 
process and product improvements.
For blinded studies, all product complaints associated with material packaged, labeled, and 
released by [CONTACT_92359] .
The designated Unblinded Site Personnel must be responsible for handling the fo llowing aspects 
of the product complaint process in accordance with the instructio ns provided for this study :
recording a complete descript ion of the product complaint reported and any associated 
AEs using the study -specific co mplaint form s provided for this purpose
faxing the completed product complaint form wit hin 24 hours to Lilly or its designee
filing the product complaint and associated records in a secure locat ion, separate from 
blinded site staff
If the invest igative site is asked to return the product for invest igation, the designated Unblinded 
Site Personnel will return a copy  of the product complaint form wit h the product.
Patients will be instructed to contact [CONTACT_81129] a 
complaint or probl em wi th the invest igational product so that the situation can be assessed.
9.3. Treatment of Overdos e
Refer to the IB.
I1F-MC-RHCR(b) Clinical Protocol Page 54
LY24398219.4. Safety
9.4.1. Laboratory Tests
For each patient, l aboratory  tests detailed in ( Appendix 2 ) shoul d be conducted according to the 
Schedule of Act ivities (Secti on 2).
With the exception o f laboratory  test resul ts that may unblind the study , Lilly or its desi gnee will 
provi de the invest igator with the results of laboratory  tests analyzed by  [CONTACT_112726] , if a 
central  vendor i s used for the clinical trial.
Any c linically  significant findings from laboratory tests that result in a diagnosis and that occur 
after the pati ent receives the first dose of study  drug shoul d be reported to Lilly  or its designee as 
an AEvia eCRF .
9.4.2. Immunogenic ityAssessments
Samples for immunogenicit y testing including a pharmacokinet ic sample will be collected at 
Vis
it 2, and at later time points in case of event judged by [CONTACT_140800] a potential 
systemic allergic/hypersensit ivity react ion, when possible.  Venous blood samples 
(approximately 10 mL) will be co llected in tubes and used to determine antibody production 
against ixekizumab .  The actual  date of  each sa mpling will be recorded on the laboratory  
requi sition.  To analyze change from baseline, the exploratory  sample collected at Vi sit [ADDRESS_301729] .
Samples fro m patients treated with guselkumab will not be analyzed for anti -gusel kumab 
antibodies.  These samples will b e discarded at the end of the study .  Immunogenicit y will be 
assessed by
 a validated assay designed to perform in the presence of ixekizumab.  Ant ibodies 
may be further chara cterized and/or evaluated for their abilit y to neutrali ze the activit y of 
ixekizumab .  Sam pleswill be retained for a maximum of [ADDRESS_301730] s related to the study  drug .Any samples remaining after 15 
years wi ll be destroy ed.
[IP_ADDRESS]. Ixekizumab Serum Concentration
Immunogenicit y samples may  also be analyzed for ixekizumab serum concentrations to facilitate 
the interpretation of the immunogenicit y data if needed .  Analysis o f samples collec ted from 
guselkumab -treated pati ents i s not pl anned.  Sam ples sent for ixekizumab serum concentration 
analysis will be tested at a laboratory  approved by [CONTACT_47551] i ts desi gnee.  Concentrations of 
immunoreactive ixekizumab in human serum will be determined by a validated method .
Bioanaly tical samples collected to m easure invest igational product concentration will be retained 
for a maximum of [ADDRESS_301731] patient visit for the study .
I1F-MC-RHCR(b) Clinical Protocol Page 55
LY24398219.4.3. Physical Examination
One co mplete physical examinat ion (excluding pelvic, rectal, and breast examinat ions) will be 
perform ed at screening.  This examinat ion will determine whether the patient meets the criteria 
required to parti cipate in the study  and will also serve as a monitor for preexist ing condit ions and 
as a baseline for treatment -emergent AE (TEAE) assessme nt.  All physical examinat ionsshoul d 
include a symptom -directed physical evaluat ion as well as an examinat ion of the heart, lungs, 
and abdo men and a visual examinat ion of the skin .
Any clinically  significant findings from a complete physical examinat ion that result in a 
diagnosis are to be reported to Lilly  or its desi gnee as AEs via eCRF .
9.4.4. Chest X-Ray and Tuberculosis Testing
An anterior -posteri orview chest x -ray will be obtained, unless the x -ray or resul ts from a chest 
x-ray obtained wi thin [ADDRESS_301732] ion prior to 
rando mizat ion.
In addit ion, pati ents will be tested at screening as indicated in Secti on 2for evidence of active or 
latent TB using the QuantiFERON ®-TB Gol d test (according to “ Guidelines for Using the 
QuantiFERON ®-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United 
States ”[CDC (WWW)], or other published regio nal recommendat ions as applicable) .  
Thismay 
be perform ed by a Lilly -designated or l ocal laboratory .  If the Quant iFERON ®-TB Gol d test i s 
indeterminate, [ADDRESS_301733] be done by [CONTACT_248181] ®-TB Gol d.  If the retest is 
indeterminate, then the patient will be excluded from the study .
Patients wi th docum entati on of  a negat ive test result with in 3 m onths before baseline (Week 0, 
Visit2) do not need a TB screen at Visit 1.
However, patients with a positive Quant iFERON ®-TB Gold test at screening but with no other 
evidence of active TB may  be re-screened 1 time and may  be enrolled wi thout repeati ng a 
Quant iFERON ®-TB GOLD test if the fo llowing condi tions a re met:
after receiving at least 4 weeks of appropriate latent TB infection therapy ,
with no evidence o f hepatotoxicit y (ALT/AST must remain ≤2xULN) upon retesting of 
serum  ALT/AST pri or to randomization.  Such patients must complete appropriate latent 
TB infect ion therapy  during the course of the study  to rem ain eligible, and 
meet all other inclusio n and exclusion criteria for participat ion.
If re-screening occurs within [ADDRESS_301734] wit h a person with active TB will be excluded, 
unless appropriate and documented prophy laxis for TB was given .
I1F-MC-RHCR(b) Clinical Protocol Page 56
LY24398219.4.5. Columbia -Suicide Severity Rating Scale
The C -SSRS is a scale that captures the occurrence, severit y, and frequency  of suicidal ideation 
and/or behavior during the assessment period.  The scale includes suggested questions to solicit 
the type of  information needed to determine if suicidal ideat ion and/or behavior occurred.  The 
C-SSRS is administered by [CONTACT_248182] h at l east 1 y ear 
of patient care/clinical experience or some or all of the patients may have this data solicited 
through electronic pat ient-reported outcomes (ePRO) technol ogy.  The tool  was developed by  
[CONTACT_248183] (TASA) for the purpose of being a counterpart 
to the Columbia Classificat ion Algori thm of Suicide Assessment categorization o f suicidal 
events .Patients will be assessed according to the Schedule of Act ivities(Secti on 2).The 
Self-Harm Suppl ement Form  is a 1-question form that asks for the number of suicidal or
nonsuicidal self -injuri ous behaviors the patient has experienced since the last assessment. For
each unique event ident ified, a questionnaire (Self -Harm  Follow
-Up Form ) which collects
supplemental  inform ation on the self -injuri ous b ehavi or is to be com pleted .The Self -Harm
Suppl ement Form  will be com pleted according to the Schedule of Act ivities (Secti on 2).
The non -leading AE collect ion shoul d occur pri or to the collect ion of the C -SSRS.  If a 
suicide-related event is discovered during the C -SSRS ,but was not captured during the 
non
-leading AE collect ion, sites shoul d not change the AE form.  If an event is serious or leads 
to discont inuat ion, this is an except ion where the SAE and/or AE leading to discont inuat ion 
shoul d be incl uded on the AE form  and the process for reporting SAEs should be fo llowed.
9.4.6. Safety Monitoring 
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by [CONTACT_82393] .
[IP_ADDRESS]. Neutropenia
During treatment with study drug ,patients with neutrophil counts <1500 cells/ L should be 
managed for neutropenia as fo llows:
<500 cells/ L (<0.50x 103/L or <0.50 GI/L) , see discontinuat ion criteria (Secti on8.1.1 )
≥500 cells/ L and <1000 cells/ L (≥0.50x10 3/Land <1.00x10 3/Lor ≥0.50 GI/L and 
<1.00 GI/L), see discont inuat ion criteria (Secti on8.1.1 )
≥1000 cells/ L and <1500 cells/ L (≥1.00x10 3/Land <1.50x10 3/Lor ≥1.00 GI/L and 
<1.50 GI/L), and the patient has a concurrent infection t hat requires systemic 
anti-infective therapy ( e.g., antibiot ic, ant ifungal  agent, and antiviral agent):
oThe dose of study  drug shoul d be wi thheld, the patient should receive appropriate 
medical care, and a repeat test for neutrophil count should be perform ed wi thin 
4weeks from knowledge of the init ial report.  If the repeat neutrophil count has 
returned to ≥1500 cells/ L (≥1.50x10 3/Lor ≥1.50x10 3/L)and the infect ion has 
resolved or is reso lving, the patient may resume dosing of study  drug and 
evaluat ionat scheduled visits.  If the neutrophil count remains ≥1000 cells/ L and 
<1500 cells/ L (≥1.00x10 3/Land <1.50x10 3/Lor ≥1.00 GI/L and <1.50 GI/L), 
study  drug shoul d cont inue to be withheld and a repeat neutrophil count should 
I1F-MC-RHCR(b) Clinical Protocol Page 57
LY2439821again be performed within another 4 weeks.  If, after 2 repeat tests, the neutrophil 
count still remains ≥1000 cells/ L and <1500 cells/ L (≥1.00x10 3/Land 
<1.50x10 3/Lor ≥1.00 GI/L and <1.50 GI/L), and:
a.the infect ion has not fully  resolved, the pati ent will be discontinued from 
the study .
b.the infect ion has reso lved, the patient may resume dosing and evaluat ion 
at scheduled visit s.  However, if resumpt ion of dosing is not deemed 
appropri ate by  [CONTACT_17062], the pati ent will be discontinued fro m the 
study .
≥1000 cells/ L and <1500 cells/ L (≥1.00x10 3/Land <1.50x10 3/Lor ≥1.00 GI/L and 
<1.50 GI/L), and the patient has no concurrent infection that requires systemic 
anti-infective ther apy (e.g., antibiot ic, ant ifungal  agent, and antiviral agent):
oDosing may continue, and a repeat neutrophil count should be performed 4 to 
8weeks from knowledge of the init ial report.  Testing may be at a regularly 
scheduled visit or at an unscheduled visit, as necessary .
oRepeat testing should be performed at 4 -to 8-week intervals unt il the neutrophil 
count has returned to ≥1500 cells/L (≥1.50x103/L or ≥1.50 GI/L) .  If the patient 
has 3 or m ore postbaseline neutrophil counts of ≥1000 cells/L (≥1.00x10 3/L or 
≥1.00 GI/L) and <1500 cells/L (<1.50x10 3/L or <1.50 GI/L) , no value of 
<1000 cells/L (<1.00 x10 3/L or <1.00 GI/L) , and no postbaseline infection 
requi ring systemic ant i-infective therapy , the pati ent m ay cont inue or resume 
further eval uation at scheduled visit s, as deemed appropriate by  [CONTACT_17062].
If a patient without init ial concurrent infection develops an infection that requires systemic 
anti-infective therapy, then the patient should be managed as indicated above for patients with 
concurrent infect ion.  Management of neutropenia during the Post -Treatment Follow -Up Peri od 
(Peri od 4) is described below.
If, at the last scheduled visit or ETV , the pati ent’s neutrophil count is <1500 cells/ L 
(<1.50x10 3/L or <1.50 GI/L) and less than the pati ent’s baseline neutrophil count, the 
following measures should be taken:
[1] Patients wi th concurrent infect ion:  if there is a concurrent infect ion that requires 
systemic anti -infect ive therapy, the patient should receive appropriate medical care and a 
repeat test for neutrophil count should be performed at least Q4W (or sooner as 
appropriate) until reso lution of infect ion.  Upon resolut ion of infection, the neutrophil 
count sho uld be monitored using the required study visits in Period 4 design at Visi ts801 
([ADDRESS_301735] ion), 802 (8weeks after Visit 801), and 803 (if 
necessary; 12 weeks after Visit 802).  Addi tional visi ts may be requi red depending on the 
degree of neutropenia.
[2] Patients wi thout concurrent infect ion:  if there is no concurrent infection that requires 
systemic anti -infect ive therapy, the neutrophil count should be mo nitored using the 
requi red study  visits in Period 4 design atVisits 801 ([ADDRESS_301736] regularly 
I1F-MC-RHCR(b) Clinical Protocol Page 58
LY2439821scheduled visit), 802, and 803 (if necessary ).  Additi onal visits may be requi red 
depending on the degree of neutropenia.
[3] For Vi sit 801 and subsequent visits, the following monitoring applies:
As long as a pati ent’s neutrophi l count is <1000 cells/ L (<1.00x10 3/L or 
<1.00 GI/L) at any fo llow-up visi t, the patient shoul d return for vi sits at least 
Q4W (may  requi re unscheduled visits).
As long as a pati ent’s neutrophil count is ≥1000 cells/ L and <1500 cells/ L 
(≥1.00x10 3/Land <1.50x10 3/Lor ≥1.00 GI/L and <1.50 GI/L) at any 
follow
-up visit, the patient should return for addit ional visit(s) at least every 4 to 
8weeks (may require unscheduled visits).
If, at Vi sit 802 or Visit 803, the pati ent’s neutrophil count is ≥1500 cell s/L 
(≥1.50x10 3/L or ≥1.50 GI/L) or greater than or equal to the patient’s baseline 
neutrophil count (whichever is lower), the patient’s participat ion in the study will 
be considered co mplete unless the invest igator determines addit ional follow-up 
may be necessary .
If, at Vi sit 803, the pati ent’s neutrophil count remains <1500 cells/ L (<1.50x10 3/L or 
<1.50 GI/L) and is less than the patient ’s baseline neutrophil count, or if the invest igator 
determines addit ional follow-up m ay be necessary , the investigator in consultation wit h Lilly, or 
qualified designee, will determine the appropriate management of the patient and the appropriate 
timing of addit ional contact(s) or visit(s).
[IP_ADDRESS]. Hepatic
If a study  patient experiences elevated ALT ≥3xULN, ALP ≥2xULN , or el evated TBL ≥2xULN, 
liver testi ng (Appendix 4 ) shoul d be repeated wi thin [ADDRESS_301737], TBL, and ALP should 
continue until levels normalize or return to approximate baseline levels .
[IP_ADDRESS].1. Hepatic Safety Data Collection
Addit ional safet y data should be co llected via the eCRF if 1 or more of the fo llowing condi tions 
occur :
elevation of serum  ALT to ≥5xULN on 2 or more consecut ive blood tests
elevated serum TBL to ≥2xULN (except for cases of known Gilbert’s 
syndro me)
elevation of serum  ALPto ≥2xULN on 2 or more consecut ive blood tests
patient discont inued fro m treatm ent due to a hepatic event or abnormal ity of 
liver tests
hepatic event considered to be a SAE
I1F-MC-RHCR(b) Clinical Protocol Page 59
LY24398219.4.6.3. Hepatitis B Monitoring
Patients who are negative for hepat itis B surface antigen (HBsAg -)and positive for anti-hepat itis 
B core antibody  (HBcAb+ )at screening, regardless of other hepatit is B testing results, will have 
a serum  HBV DNA obtained to be analyzed by [CONTACT_2237] .  Pati ents who are 
determined to be HBV DNA negative (undetectable) may be enrolled into the study  with 
requi red HBV DNA mo nitoring every  [ADDRESS_301738] 
dose of ixekizumab .  Pati ents who are found to be HBV DNA posit ive (detectable) at screening 
will be excluded fro m the trial(see “ Interpretation o f Hepatitis B Serologic Test Results ” [CDC 
resources page (WWW)], or other published regio nal recommendat ions as applicable).
Any enrolled pat ient with a posi tive HBV DNA test results at any t ime must be di scont inued 
from the study  and shoul d receive appropri ate fo llow-up medical care, including considerat ion 
for antiviral therapy .
Study  investigators should consult with a specialist physician in the care of patients with 
hepat itis (e.g., infectious disease or hepatologist subspecialists) on whether to continue any 
immunosuppressant therapy  including study  drug for a peri od of  time while ant iviral therapy is 
being init iated.  Timing of wit hdrawal f rom study  drug shoul d be based on recommendation of 
the consult ing specialist physician in conjunction with the invest igator and local or regional 
medical guidelines or standards of care .
Upon discont inuat ion from study  drug, the pati ent shoul d be discont inued fro m the study .  Any  
patient who di scontinued the study  for any  reason will co mplete the ETV before entering the 
Post-Treatment Follow -Up Peri od (Peri od 4) .
9.5. Pharmacokinetics
See Secti on [IP_ADDRESS] .
9.6. Pharmacodynamics
Not applicable.
9.7. Pharmacogenomic s orGenetics
Not applicable.
9.8. Biomarkers
Not applicable.
9.9. Health Economics orMedical Resource Utilization and Health 
Economics
Not applicable.
I1F-MC-RHCR(b) Clinical Protocol Page 60
LY243982110. Statistical Considerations
10.1. Sample Size Determination
Approximately  960 patientswill be rando mized at a 1:[ADDRESS_301739] 
98% power to test the superiorit y of ixekizumab 80 mg Q2W to guselkumab 100 mg Q8W for 
PASI 100 at Week 12. The following assumpti onswere used for the power calculation response 
rate at Week 12: 35.3% and 23.0% for ixekizumab and guselkumab group, respectively . A 
2-sided Fisher ’sexact test at significance level 0.0 5is assumed .  These assumpt ionsare based on 
the ixekizumab and guselkumab clinical studies in Ps(Griffit hs et al . 2015 ; Gordon et al. 2016 ;
Blauvel t et al . 2017 ;Reich et al. 2017 ).
This study  is also powered at 95% to test the superiorit y of ixekizumab for PASI 100 at Week 24 
assuming the response rate of ixekizumab and guselkumab at 56% and 44%, respectively .
10.2. Populations for A nalyses
Unless otherwise specified, efficacy  and heal th outcom e analyses will be conducted on the 
intent-to-treat (ITT) populat ion; whereas ,safet y analyses will be conducted on the safet y 
popul ation defined below:
Population Description
Intent -to-TreatPopulation All randomized patients, even if the patient does not take the assigned treatment, 
does not receive the correct treatment, or otherwise does not follow the protocol. 
Patients will be analyzed according to the treatment to which they were 
assigned.
Safety All randomized participants who take at least [ADDRESS_301740] ical 
analysis purposes. All efficacy and health outcomes analyses will use pooled sites.
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301741] ion Dosing Period (Peri od 2) starts at the first inject ion of study  drug at Week 0 
(Visit 2) and ends prior to the first inject ion of study  drug at Week 1 2 or the ETV (between 
Weeks 0 and 12).
Baseline will be defined as the last available value before the first inject ion for efficacy, healt h
outcom es,and safet y analyses. In most cases, this will be the measure recorded at Week 0 
(Visit2). For efficacy measures, if the patient does not take any  inject ion, the last available 
value on or prior to therando mizat ion date will be used. Change fro m baseline will be 
calculated as the visit value of interest minus the baseline value. For safet y analyses using a 
baseline period, the baseline period is defined as the time from Visit 1 to the date/time of the first 
inject ion.
The primary  analysis method for treatment comparisons of categorical efficacy, healt h outcom es
variables at specific time po ints will be made using a Cochran -Mantel -Haenszel (CMH ) test 
stratified by [CONTACT_87843]. Missing data will be imputed using the nonresponder imputation ( NRI)
method .  The 95% confidence interval (CI)associ ated wi th the treatment response rate, and 
treatm ent difference will be provided .  Secondary analysis will be conducted using a Fisher ’s 
exact test.
The primary  analyses for the continuous efficacy and healt h outcome variables will be performed 
using mixed effects model for repeated measures (MMRM) analysis.  The model will include 
treatment, pool ed site, baseline value, visit, treatment -by
-visit interacti on and baseline 
value -by-visit as fixed factors .  A secondary analysis for continuous efficacy and healt h 
outcom es variables will be made using analysis o f covari ance (ANCOVA) adjust ing for pool ed 
siteand baseline value.
Fisher ’s exact test will be used for all AE, baseline, discontinuat ion, and other categorical safet y
data.  Continuous laboratory values will be analyzed by [CONTACT_248184] .
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the clinical study  report (CSR) .  Additional exploratory analyses of the data will be conducted 
as deemed appropriate.
10.3.2. Treatment Group Comparability
[IP_ADDRESS]. Patient Disposition
All patients wh o discont inue from the study  will be identified, and the extent of their
participat ion in the study will be reported .  If known, a reason for their discont inuat ion will be
given.
I1F-MC-RHCR(b) Clinical Protocol Page 62
LY2439821Patient disposi tion will be summarized for each treatment period .  Reasons fo r discont inuat ion
from the study  will be tabul ated by  [CONTACT_248185]. A detailed descript ion of pat ient 
disposi tion will  be provi ded at the end of the study. 
[IP_ADDRESS]. Patient Characteristics
Patient characterist ics and baseline clinical measures will be recorded and summarized by 
[CONTACT_248186] . Baseline characterist ics will include gender, age , height, wei ght, race, durati on 
of disease, previ ous nonbi ologic systemic therapy , and previ ous bi ologic therapy .Baseline 
clinical and heal th outcom e measurements will include sPGA, PASI, BSA , Itch NRS, DLQI, 
skin pain and pati ent gl obal assessment ,PGA -F, physician’s global a ssessme nt of disease 
activit y VAS ,patient’s assessment of pain VAS ,patient’s glo bal asses sment of di sease act ivity 
VAS, and C -SSRS .
Comparisons between t reatment groups will be conducted using Fisher ’s exact test and analysis 
of variance (ANOVA) forcategorical data and continuous data, respectively.
[IP_ADDRESS]. Concomitant Therapy
Previous and concomit ant m edicat ionswill be summarized for patients who enter each treatment 
period and presented by  [CONTACT_248187] (WHOATC) 
Level 4and generic name.
[IP_ADDRESS]. Treatment Compliance
Treatment compliance wit h study  drug will be summarized for each treatment period separately . 
Overall compliance with therapy  is defined to be missing no more than 20% of the expected 
doses and not missing 2 consecuti ve doses. A patient will be considered co mpliant overall for 
each study  period if he/she is missing no more than 20% of the expected doses and not missing 
2consecutive doses. Proporti ons of patients compliant by  [CONTACT_248188] .  Detailed analyt ical method for comparison will be defined in the 
statist ical analysis plan (SAP).
10.3.3. Efficacy Analyses
[IP_ADDRESS]. Primary Analyses
The primary  analysis ,that is,the proporti on of  patients who achieve PASI [ADDRESS_301742] 
stratified by [CONTACT_87843]. Missing data will be imputed using the NRI method .The 95% CI 
associ ated wi th the treatm ent response rate, and treatme nt difference will be provided.
Secondary  analyses for PASI 100at Week 12 will be conducted using Fisher ’s exact test .
[IP_ADDRESS]. Major Secondary Analyses
Table RHCR. 10.1 summarizes the primary and major secondary outcomes and analysis methods.
All analyses listed will be performed based on the ITT Populat ion unless otherwise specified .
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301743] visit within the treatm ent peri od. Both the 
date/time of the event onset and the date/time of the first study drug inject ion are considered 
when determining TEAEs. Treatment -emergent adverse event swill be assigned to the treatment 
period in which they  first occurred or worsened. A follow-up emergent AE(FEAE) is defined as 
an event that first occurred or worsened in severit yafter the date of Week 24 or the ETV. For 
events that are gender specific, the deno minator and computation of the percentage will include 
only patients from  the gi ven gender .
An overall summary o f AEs will be provided for each o f the treatment periods, including the 
number and percentage of patients who experienced TEAEs, TEAEs by  [CONTACT_41425], 
deaths, SAEs, TEAEs related to study  drug, discontinuat ions from the treatm ent due to an AE,
and treatment -emergent AESIs. Treatment -emergent AEs (all, by  [CONTACT_41424] y, and 
TEAEs possibly related to st udy drug by [CONTACT_093]), SAEs including deaths, and AEs that 
lead to treatment discont inuat ion will be summarized and analyzed by [CONTACT_248189], and Preferred T erm.
In addit ion to general sa fety param eters, safet y inform ation on specific topi [INVESTIGATOR_248156]. Poten tial AESIs will  be ident ified by a standardized MedDRA query or a Lilly 
defined MedDRA preferred term list ing.
Follow-up em ergent adverse events, SAEs including d eaths, and AEs that lead to study
discontinuat ionwill be summarized for Post-Treatment Follow -Up Period(Peri od 4) .
[IP_ADDRESS]. Clinical Laboratory Tests
Laboratory  assessments will be presented as mean changes from baseline, and as incidence of 
treatm ent-emergent abnormal, high, or low laboratory  values (see below). Shift tables will be 
presented for selected parameters.
For categorical lab tests:
oTreatment -emergent abnormal value = a change from  norm al at all  baseline visits
to abnormal at any  time post baseline.
For continuous l ab tests:
oTreatment -emergent high value = a change fro m a value less than or equal to the
high limit at all baseline visits to a value greater than the high limit at any  time
post baseline.
oTreatment -emergent lowvalue = a change from a value greater than or equal to
the low limi t at all  baseline visi ts to a value l ess than the l ow limi t at any  time
post baseline.
[IP_ADDRESS]. Other Safety Evaluations
Suicide-related thoughts and behaviors and self- injuri ous behavior with no suicidal intent, based 
on the C -SSRS, will be listed by  [CONTACT_4676].
Further details for these analyses will be provided in the SAP.
I1F-MC-RHCR(b) Clinical Protocol Page 65
LY243982110.3.5. Evaluation of Immunogenicity
For pati ents randomized to ixekizumab who experience a potenti al systemic 
allergic/hypersensit ivityevent during the study, an immunogenicit y sample will be co llected and 
evaluated for ADA co mpared to a stored baseline sample if possible .Immunogenici ty samples 
will not be evaluated for anti-guselkumab antibodies .
10.3.6. Other Analyses
[IP_ADDRESS]. Subgroup Analyses
The effect of the fo llowing baseline characterist ics on the primary efficacy endpoint, PASI 100 
at Week 12, willbe assessed:
Demographics ( e.g., gender, age, weight, and race)
Disease characterist ics (e.g., disease severit y, durati on of disease, and age o
fonset)
Previous treatm ent for Ps(e.g., previous use of nonbio logic systemic therapy , and 
previous use of biologic therapy )
Detailed descript ion of the subgroup variables will be provided in the SAP. Addit ional subgroup
analyses on efficacy or subgroup analyses on safety may be performed as deemed appropriate
and necessary.
10.3.7. Interim Analyses
One interim analys is is planned when all patients have co mpleted their Week 12 visit or ETV . 
The interim analys iswill include all data collected by  [CONTACT_81280], including the data from the 
Extensio n Period(Peri od 3) and the Post Treatment Follow- Up Period(Peri od 4) .The analyses 
from the Week [ADDRESS_301744] co mpleted the study  (or di scont inued 
on or prior to Week 24) and final database l ock has occurred.  Site staff, clinical mo nitors, and 
patients will  remain blinded to the patient treatment allo cation unt il after final database lock .
Inform ation that m ay unblind the study  during the analyse s will  not be reported to study  sites or 
blinded study  team  until  the study  has been unblinded. All investigators, patients and personnel 
in contact [CONTACT_248190] .
Addit ional analyses and snapshots of study  data may  be performed after all pat ients com plete 
Period 3 (Week 24 or ETV) to fulfill the need for regulatory  interacti ons or publicat ion purposes.
Unblinding details are specified in the unblinding pl an sect ion of the SAP or a separate 
unblinding plan document.
I1F-MC-RHCR(b) Clinical Protocol Page 66
LY243982111. References
Barto s S, Hill D, Feldman SR. Review o f maintenance o f response to psoriasis treatments. J 
Dermatolog Treat . 2016;27:293-297.
Blauvel t A, Papp KA, Griffit hs CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Efficacy 
and safet y of guselkumab, an anti- interleukin- 23 monocl onal ant ibody , com pared wi th 
adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results 
from the phase III, double - blinded, pl acebo -and active co mparator -controlled VOYAGE 1 
trial. 
J Am Acad Dermatol .2017;76:[ADDRESS_301745] Monograph. Available at: https://www.lilly.ca/en/pdf/product -monograph/tal tz-
pm-english.pdf .Accessed June 14, [ADDRESS_301746] Monogr aph. Available at: 
https://www.j anssen.com/canada/sites/www_janssen_co m_canada/files/prod_files/live/tremfy
a_cpm .pdf. Accessed June 14, 2018 .
CDC resources page. Centers for Disease Control and Prevention web site. Available at: 
https://cdc.gov/mmwr/previe w/mmwrht ml/rr5415a4.htm . Accessed June 14, 2018 .
CDC resources page. Centers for Disease Control and Prevention web site. Available at: 
https://www.cdc.gov/hepat itis/hbv/pdfs/sero logicchartv8.pdf . Accessed June 14, 2018 .
Christophers E. Psoriasis —epi[INVESTIGATOR_248157] . Clin Exp Dermatol.
2001;26(4):314 -320.
Dubin DB, Tanner W, Ellis R. Bio logics for psori asis. Nat Rev Drug Discov.
2003;2(11):855 -856.
[EMA] European Medicines Agency. Committee for medicinal products for human use (CHMP). 
Guideline on clinical invest igation of medicinal products indicated for the treatment of 
psori asis. November 2004. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library /Scient ific_guideline/2009/09/WC50
0003329.pdf . Accessed June 5, 2018 .
Fairchild AO, Reed SD, Johnson FR, Anglin G, Wolka AM, Noel RA. What i s clearance worth? 
Patients’stated risk tolerance for psoriasis treatments. J Dermatolog Treat . 
2017;28(8):[ADDRESS_301747] cl ear skin in clinical practice. J Dermatolog Treat . 
2016;27(3):224 -227.
Fredri ksson T, Pettersson U. Severe psoriasis —oral  therapy wi th a new retino id. Dermatologica . 
1978;157(4):238 -244.
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myo cardi al 
infarction in pat ients with psori asis. JAMA . 2006;296(14):1735- 1741.
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball 
SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nicko loff BJ, Osuntokun 
OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER- 1 Study  Group; UNCOVER -2 
I1F-MC-RHCR(b) Clinical Protocol Page 67
LY2439821Study Group; UNCOVER -3 Study  Group. Phase 3 Trials of ixekizumab in moderate- to-severe 
plaque psori asis. N Engl J Med. 2016;375(4):345 -356.
Gordon KB1, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary  P, 
Randazzo B, Reich K. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. 
N Engl J Med . 2015;373:136 - 144.
Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffit hs 
CEM. Efficacy  of guselkumab in subpopulat ions of pat ients wi th moderate -to-severe plaque 
psori asis: a pool ed analysis o f the phase III Voy age 1 and Voy age 2 studi es. Br J Dermatol
2018; 178:22.
Gowda S, Goldblum OM, McCall WV, Feldman SR. Factors affect ing sleep qualit y in pat ients 
with psoriasis. J Am Acad Dermatol . 2010;63(1):114 -123.
Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of  long-term drug 
survival and safet y of biologic agents in pati ents wi th psori asis vulgaris. Br J Dermatol . 
2015;172:[ADDRESS_301748] RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nicko loff BJ, Papp 
K; UNCOVER -[ADDRESS_301749] igators . Com parison of ixekizumab wit h etanercept 
or placebo in m oderate -to-severe psoriasis (UNCOVER -2 and UNCOVER -3): results from 
two phase 3 rando mised trials. Lancet.2015; 3 86:541 - 5 51.
[IFPA] International Federat ion of Psoriasis Associat ions. Profile o f psori asis page. International 
Federat ion of Psoriasis Associat ions web site. Available at: https://ifpa -pso.com /our- cause/ .
Accessed June 5, 2018 .
Janowski K, Steuden S, Bogaczewicz J. Clinical and psycho logical characteri stics of patients 
with psoriasis reporting various frequencies of pruritus. Int J Dermatol . 2014;53(7):820 -829.
Krueger JG, Ferris LK, Menter A, Wagner F, Whit e A, Vi svanathan S, Lal ovic B, Aslanyan S, 
Wang EE, Hall D, Solinger A, Padula S, Scholl P. Anti-IL-23A mAb BI 655066 for treatment 
of moderate -to-severe psoriasis: safet y, efficacy, pharmacokinet ics, and bio marker results of a 
single- rising-dose, randomized, double -blind, pl acebo -controlled trial. J Allergy Clin Immu nol.
2015;136:116 -124.e7.
Krueger JG, Fretzin S, Suárez -Fariñas M, Haslett PA, Phipps KM, Cameron GS, McColm J, 
Katcheri an A, Cueto I, White T, Banerjee S, Hoffman RW. IL -17A is essential for cell 
activat ion and inflammatory  gene ci rcuits in subjects wi th psoriasis. J Allergy Clin Immunol. 
2012;130(1):145 -154.
Langley  RG, El ewski  BE, Lebwohl M, Reich K, Griffit hs CE, Papp K, Puig L, Nakagawa H, 
Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Ty ring S, Salko T, Hampele I, Notter 
M, Karpov A, Helou S, Papavassilis C; ERASURE Study  Group; FIXTURE Study  Group.
Secukinumab in pla que psori asis –resul ts of two phase 3 trials. N Engl J Med .2014; 371: 326-
338.
Lebwohl MG, Bachelez H, Barker J, Giro lo
moni G, Kavanaugh A, Langley RG, Paul CF, Puig 
L, Rei ch K, van de Kerkho f PCM. Pati ent perspectives in the management of psoriasis: resu lts 
I1F-MC-RHCR(b) Clinical Protocol Page 68
LY2439821from the popul ation-based Mult inational Assessment of Psoriasis and Psoriat ic Arthri tis Study . 
J Am Acad Dermatol. 2014;70(5):871 -881.
Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, 
Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley  J, Langley RG, 
Blicharski T, Paul C, Lacour JP, Ty ring S, Ki rcik L, Chiment i S, Callis Duffin K, Bagel J, Koo 
J, Aras G, Li J, Song W, Milmo nt CE, Shi  Y, Erondu N, Klekotka P, Kotzin B, Nirula A.
Phase 3 studies co mpar ing brodalumab with ustekinumab in psoriasis. N Engl J Med .
2015;373 :1318-1328.
Leonardi CL , Kimball  AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon 
KB; PHOENIX 1 study  investigators. Efficacy and safet y of ustekinumab, a human 
interleukin -12/23 m onocl onal antibody
, in patients with psoriasis: [ADDRESS_301750] acebo -controlled trial (PHOENIX 1). Lancet .2008; 371: 1665-
1674.
Leonardi C, Matheson R, Zacha riae C, Cameron G, Li L, Edson -Heredi a E, Braun D, Banerjee 
S.Anti
-interleukin- 17 m onocl onal ant ibody ixekizum ab in chronic plaque psoriasis. N Engl J 
Med. 2012;366:1190-1199.
Mason J, Mason A, Cork MJ. Topi[INVESTIGATOR_248158]: 
a system atic review. York ([LOCATION_006]): Centre for Health Economics. 2002. Available at: 
https://www.y ork.ac.uk/che/pdf/op41.pdf . Accessed April 17, 2015.
Menter A1, Ty ring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, 
Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: A rando mized, 
controlled phase III trial. J Am Acad Dermatol .2008; 58:106 -115.
[NPF] Nati onal Psori asis Foundat ion. Psori asis severi ty resource page. National Psoriasis 
Foundat ion
.Available at: https://www.psoriasis.org/about -psoriasis/causes . Accessed June 5, 
2018.
Papp KA , Tyring S, Lahfa M, Prinz J, Griffit hs CE, Nakanishi AM, Zitnik R, van de Kerkho f 
PC, Melvin L; Etanercept Psoriasis Study  Group. A global phase III randomized controlled 
trial of etanercept in psoriasis: safet y, efficacy, and effect of dose reduction. Br J Dermatol .
2005; 152:1304
-1312.
Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary  P, Yeilding N, Guzzo C, Hsu MC, 
Wang Y, Li S, Dooley  LT, Rei ch K; PHOENIX [ADDRESS_301751] igators. Efficacy and safet y of 
ustekinumab, a human interleukin -12/23 m onocl onal antibody , in pat ients with psori asis: 
52-week results fro m a rando mised, double -blind, pl acebo -controlled trial (PHOENIX 2).
Lancet .2008; 371:1675
-1684.
Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, 
Bowman EP, Mehta A, Li Q, Zho u Y, Sham es R. Tildrakizumab (MK- 3222), an 
antiinterleukin -23p19 m onocl onal ant ibody , improves psori asis in a phase IIb randomized 
placebo -controlled trial. Br J Dermatol .2015;173:930 -939.
Puig L. PASI90 response: the new standard in therapeutic efficacy  for psori asis. J Eur Acad 
Dermatol Venereol . 2015;29(4):645 -
648.
I1F-MC-RHCR(b) Clinical Protocol Page 69
LY2439821Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordo n KB.
Efficacy and safet y of guselkumab, an anti- interleukin -23 m onocl onal ant ibody, co mpared 
with adalimumab for the treatment of patients with moderate to severe psoriasis wit h 
rando mized withdrawal and retreatment: Results from the phase III, double -blind, pl aceboand 
active co mparator -controlled VOYAGE 2 trial. J Am Acad Dermatol .2017;76:[ADDRESS_301752] le FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffit hs CE; 
EXPRESS study  invest igators. Infliximab induct ion and m aintenance ther apy for 
moderate -to-severe psoriasis: a phase III, mult icentre, doubl e
-blind tri al. Lancet .
2005;366:1367-1374.
Ryan C, Kirby B. Psoriasis is a systemic disease wit h multiple cardiovascular and metabo lic 
comorbidi ties. Dermatol Clin . 2015;33(1):41 -55.
Sofen H, Smit h S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, 
Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary  P, Krueger JG. Guselkumab (an IL -23-specific 
mAb) demonstrates clinical and molecular response in patients with moderate -to-severe 
psori asis. J Allergy Clin Immunol. 2014;133:1032
-1040.
Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, Ferris LK, Paul C, 
Lebwohl M, Braun DK, Mallbris L, Wilhelm S, Xu W, Ljungbe rg A, Acharya N, Rei ch K.
Short -and long -term safet y outcom es wi th ixekizumab fro m 7 clinical trials in psoriasis: 
Etanercept compar isons and integrated data. J Am Acad Dermatol . 2017;76(3):[ADDRESS_301753] cl ear 
skin in the clinical setting. J Am Acad Dermatol. 2014;71(4):633 -641.
Taltz USPI. Available at: https://pi.lilly.co m/us/taltz -uspi.pdf. Accessed June 14, 2018 .
Thoma s CL, Finlay AY. The ‘handprint’ approximates to 1% of the total body  surface area 
whereas the ‘palm minus the fingers’ does not. Br J Dematol . 2007;157(5):1080 -1081.
Tremfya USPI [package insert]. Available at: http://www.janssenlabels.co m/package -
insert/product -monograph/prescribing -information/TREMFYA -pi.pdf. Accessed June 14, 
2018.
Viswanathan H N, Chau D, Milmo nt CE, Yang W, Erondu N, Revicki DA, Klekotka P. Total 
skin clearance results in improvements in health -related quali ty of life and reduced symptom 
severit y among pati ents wi th moderate to severe psori asis. J Dermatolog Treat . 
2015;26(3):23 5-239.
Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, Shin DB, Attor R, Troxel 
AB, Gelfand JM. Psoriasis severit y and the prevalence o f ma
jor medical co morbidity: a 
popul ation-based study . JAMA Dermatol . 2013;149(10):1173- 1179.
Zimo lag I, Rei ch A, Szepi [INVESTIGATOR_110425]  J. Influence of psori asis on the abilit y to work [abstract]. 13th 
Congress of the European Societ y for Dermatology and Psychiatry; Sep 17- 22, 2009; Venice, 
Italy. Acta Derm Venereol. 2009;89:[ADDRESS_301754] OP76.
I1F-MC-RHCR(b) Clinical Protocol Page 70
LY243982112. Appendices
I1F-MC-RHCR(b) Clinical Protocol Page 71
LY2439821Appendix 1. Abbreviations and Definitions
Term Definition
ADA anti-drug antibody
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporal ly associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
AESI adverse events of special interest
ALT alanine aminotransferase
ALP alkaline phosphatase
ANCOVA analy sis of covariance
AST aspartate aminotransferase
BCG Bacillus Calmette -Guérin
Blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not.
A double -blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the subjects are
aware of the treatment received.
BSAbody surface area
CECClinical Events Committee
CFRCode of Federal Regulations
CI confidence interval
CIOMS Council forInternational Organizations ofMedical Sciences
CMH Cochran -Mantel -Haenszel
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301755] of obtaining informed consent for participation in a clinical trial from patients 
deemed eligible or potentially eligible to participate in the clinical trial.  Patients 
entered into a trial are those who sign the informed consent form directly or through 
their legally acceptable representatives.
CRF/eCRF Case report form/electronic case report form:  Sometimes referred to as clinical report 
form:  A printed or electronic form for recording study participants’ data during a 
clinical study, as required by [CONTACT_760].
CRP/CRS clinical research physician /clinical research scientist : Individual responsible for the 
medical conduct of the study.  Responsibilities of the CRP may be performed by a 
physician, CRS, global safety physician or other medical officer.
CSR clinical study report
C-SSRS Columbia -Suicide Severity Rating Scale
DLQI dermatology life quality index
DNA deoxyribonucleic acid
DSM -IV Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
EDC electronic data capture
EMA European Medicines Agency
ERB/IRBEthical review board/institutional review board:  A board or committee (institutional, 
regio nal, or national) composed of medical and nonmedical members whose 
responsibility is to verify that the safety, welfare, and human rights of the patients 
participating in a clinical study are protected.
end of stud y (trial)End of study (trial) is the date of the last visit or last scheduled procedure shown in the 
Schedule of Events for the last patient.  
enroll The act of assigning a patient to a treatment.  Patient who are enrolled in the study are 
those who hav e been assigned to a treatment.
enter Patient entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ETV Early  Termination Visit
FSH Follicle -stimulating hormone
GCP good clinical practice
HBcAb anti-hepatitis B virus core antibody
HBsAg hepatitis B virus surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
I1F-MC-RHCR(b) Clinical Protocol Page 73
LY2439821HIV human immunodeficiency virus
IB Investigator’s Brochure
IBD inflammatory bowel disease
ICF informed consent form
ICH International Council for Harmonisation
IGA Investigator Global Assessment
IgG immunoglobulin G
IL interleukin
Informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the patient’s decision to participate.  Informed consent is documented by 
[CONTACT_3553] a written, signed and dated informed consent form .
interim analysis An interim analysis is an an alysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate 
in a particul ar trial, after having been informed of all aspects of the trial that are relevant 
to the patient’s decision to participate.  Informed consent is documented by [CONTACT_3553] a 
written, signed, and dated informed consent form.  
INR internatio nal no rmalized ratio
ITT intention to treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by [CONTACT_41445] a patient (that is, the 
planned treatment regimen) rather than the actual treatment g iven.  It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.
IWRS interactive voice -response sy stem/i nteractive web -response system
LS least-squares 
MAb monoclonal antibody
MedDRA Medical Dictionary for Regulatory Activities
MI myocardial infaraction
MMRM mixed model for repeated measures
MTX methotrexate
NRI nonresponder imputation
I1F-MC-RHCR(b) Clinical Protocol Page 74
LY2439821NRS numeric rating scale
PASI Psoriasis Area and Severity Index
PASI 50/75/[ADDRESS_301756] a ( ≥)50%/ 75%/90% improvement in PASI score from baseline
PASI 100 a 100% improvement in PASI score from baseline
PatGA Patient’s global assessment of disease severity
PGA -F Physician’s Global Assessment of Fingernail Psoriasis
PK pharmacokinetics
PPS per-protocol set:  The set of data generated by [CONTACT_140845], according to the underlying scientific model.
PRO/ePRO patient -reported outcomes/electronic patient -reported outcomes
Ps plaque psoriasis
PsA psoriatic arthritis
Q2W every [ADDRESS_301757] of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
study drug A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indicat ion, or marketed products used to 
gain further information about the authorized form.
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
TB tuberculosis
I1F-MC-RHCR(b) Clinical Protocol Page 75
LY2439821TBL total bilirubin level
TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
Th T helper
TNF tumor necrosis factor
TNFi TNF inhibitor
TPO third -party organization
ULN upper limit of normal
USPI [INVESTIGATOR_248159] I nsert
VAS visual analog scale
WBC white blood cell
I1F-MC-RHCR(b) Clinical Protocol Page 76
LY2439821Appendix 2. Clinical Laboratory  Tests
Hematology a,b Serum Chemistry a,b
Hemoglobin Sodium
Hematocrit Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume (MCV) Chloride
Mean cell hemoglobin concentration (MCHC) Phospho rus
Leukocytes (WBC) Total bilirubin
Platelets Direct bilirubin
Alkaline phosphatase
Absolute counts of: Alanine aminotransferase (ALT/SGPT)
Neutrophils, segmented Aspartate aminotransferase (AST/SGOT)
Neutrophils, juvenile (bands) Blood urea nitrogen (BUN)
Lymphocy tes Uric acid
Monocytes Creatinine
Eosinophils Calcium
Basophils Glucoseg
Albumin
Urinalysis (dipsit ck)a,bCholesterol (total)
color Total protein
Specific gravity CPK 
pH Triglycerides
Protein Gamma -Glutamyl Transferase (GGT)
Glucoseg
Ketones
Bilirubin
Urobilinogen
Blood
Nitrite
Urine creatinine
Leukocyte esterase
Urinaly sis (microscopic):
Sediment, cells, casts Immunogenicity
Ixekizumab serum concentration
Other Tests a
Human immunodeficiency virus antibody (HIV) c,d
Hepatitis B Surface antigen (HBsAg) c,d Pregnancy Test (serum and urine) e
Anti-Hepatitis B Core antibody (HBcAb) c,d
Anti-Hepatitis B Surface antibody (HB sAb)dFollicle stimulating hormone (FSH)d,f
Anti-Hepatitis C antibody c,d
HBV DNA c,d
Tuberculosis d
I1F-MC-RHCR(b) Clinical Protocol Page 77
LY2439821Clinical Safety Laboratory Tests
Abbreviations:  CPK = creatine phosphokinase; DNA = deoxyribonucleic acid; HBV = hepatitis B virus ;RBC = 
red blood cells; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic pyruvic 
transaminase; WBC = white blood cells.
aAssay ed by [CONTACT_3211] -designated laboratory.
bUnscheduled blood che mistry, urinaly sis,and hematology panels may be performed at the disc retion of the 
investigator .
cSee exclusion criteria (Section 6.2).
dTest required at Visit 1 only to determine eligi bility of patient for the study (note: with the exception of those 
patients who re quire fu rther HBV monitoring [ Section [IP_ADDRESS] ]).
eSerum pregnancy test (women <60 years of age who are still of childbearing potential) and urine pregnancy test 
(women of childbearing potential).  Patients will undergo urine pregnancy self -testing at home on a monthly 
basis during periods between scheduled visits until Week 24.  During these intervisit periods, the s ite must call 
the patient each month to obtain her pregnancy test results.  Additional urine pregnancy testing can be performed 
at the investigator’s discretion.  Patients determined to be pregnant will be discontinued from treatment and will 
no lo nger be administered study drug (see Section 8.1.1).
fWomen ≥40 and <[ADDRESS_301758] had a cessation of menses for ≥[ADDRESS_301759] 
confirming nonchildbearing potential ( ≥40 mIU/mL).  FSH test will be perfo rmed centrally .
gnon
-fasting glucose .
I1F-MC-RHCR(b) Clinical Protocol Page 78
LY2439821Appendix 3. Study  Governance Considerations
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301760] igator is responsible for:
ensuring that the patientunderstands the nature of the study , the potential risks 
and benefits of participat ing in the study , and that their participat ion is vo luntary.
ensuring that informed consent is given by [CONTACT_248191].  
This includes obtaining the appropriate signatures and dates on the informed 
consent form ( ICF) prior to the performance of any  protocol  procedures and pri or 
to the administration of study  drug .
answering any quest ions the patient/ may have throughout the study  and sharing in 
a timely manner any  new informat ion that m ay be rel evant to the patients 
willingnes sto continue his or her participat ion in the study .
ensuring that a copy  of the ICF is provi ded to the participant or the participant’s 
legal representative and is kept on file.
ensuring that the medical record includes a statement that written informed 
consent was obtained before the participant was enrolled in the study  and the date 
the wri tten consent was obtained. The authorized person obtaining the informed 
consent must also sign the ICF.
Appendix 3.1.[ADDRESS_301761] (ERB) was properly 
constituted and convened as required by [CONTACT_157732] (ICH) 
guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by [CONTACT_41429], before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guideline on Good Clinical Pract ice (GCP ).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
theprotocol and related amendments and addenda ,current Invest igator Brochure 
(IB)and updates during the course of the study
inform ed consent form  
other relevant docum ents ( e.g., curricula vitae , adverti sements)
I1F-MC-RHCR(b) Clinical Protocol Page 80
LY2439821Appendix 3.1. 4. Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with the:
consens us ethi cs principles derived from internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council forInternational Organizati onsof
Medical Sciences (CIOMS ) Internati onal Ethi cal Gui delines
applicable ICH GCP Guidelines
applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party .
Appendix 3.[ADDRESS_301762] igators 
in this cl inical trial.
Appendix 3.1. 6. Protocol Signatures
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Appendix 3.1. 7. Final Report Signature
[CONTACT_248197] (CSR) for this study, indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The CSR coordinat ing invest igator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study .
The invest igator with the m ost analyzable and enrolled patients will serve as the CSR 
coordinat ing investigator.  If this invest igator is unable to fulfill this funct ion, another 
investigator will be chosen by  [CONTACT_248192].
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study , confirming that to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
I1F-MC-RHCR(b) Clinical Protocol Page 81
LY2439821Appendi x 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
provi de sponsor start- up training to instruct t he investigators and study 
coordinators.  This training will give instruction on the protocol, the complet ion 
of the CRFs, and study  procedures
make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_248193], tel ephone, and/or fax
review and verify  data reported to detect potential errors 
In addit ion, Lilly or its representatives will periodically check a sample of the pati ent data 
recorded against source documents at the study  site.  The study may be audited by  [CONTACT_47551] i ts 
representatives and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edica l records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
Appendix 3.2.1. Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data capture (EDC) system  will be used in this study  for the collect ion of CRF 
data.  The investigator maintains a separate source for the data entered by  [CONTACT_32864] -provided EDC system.  The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  [CONTACT_11003] .
Clinical outcome assessment (COA) data (questionnaires) will be co llected by [CONTACT_248194], vi a a paper source document and will be transcribed by  [CONTACT_248195].
Addit ionally , electroni c Clini cal Outcom e Assessment (eCOA) data ( questionnaires, scales, 
rating scales etc. ) will be direct ly recorded by [CONTACT_423]/investigator site personnel, into an
instrum ent (e.g. , hand held tablet). The eCOA data will serve as the source documentation and 
the invest igator does n ot maintain a separate, written or electronic record of these data.
Data collected via the sponsor- provided data capture system (s) will b estored at a third -party  site.  
The invest igator will have cont inuous access to the data during the study  and unt il 
decommissio ning of the data capture sy stem (s).  Prior to decommissio ning, the invest igator will 
receive an archival copy  of pertinent data for retention.
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301763] data, will be stored electronically  in 
the central  vendor’s database system and electronic transfers will be provi ded to the invest igator 
for review and retent ion.  Data will subseque ntly be transferred fro m the central  vendor to the 
Lilly Clinical Laboratory  Results Modernizat ion database.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
Appendix 3.3. Study and Site Closure
Appendix 3.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inuedif Lilly , the invest igator, or the ERB of the study  
sitejudges it necessary for medical, safety , regul atory , or other reasons consistent with 
applicable laws, regulat ions, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be di scont inued if Lilly judges it necessary for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 3. 4. Publication Policy
The publicat ion policy for Study  I1F-MC-RHCR is described inthe letters of agreem ent between
the Sponsor and the invest igators and inst itutions.
I1F-MC-RHCR(b) Clinical Protocol Page [ADDRESS_301764] Anti -smooth muscle antibody (or anti -actin 
antibody) a
GGT
CPK
Abbreviations:  ALT = alanine aminotransferase; AST = aspi[INVESTIGATOR_82355]; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; RBC = red blood cells; 
WBC =white blood cells.
aAssay ed by [CONTACT_11007] -designated or local l aboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I1F-MC-RHCR(b) Clinical Protocol Page 84
LY2439821Appendix 5. Protocol A mendment I1F -MC-RHCR( b) 
Summary :A 24 Week Multicenter, Randomized, Double 
Blind, Parallel Group Study  Comparing the Efficacy  and 
Safety  of Ixekizumab to Guselkumab in Patients with 
Moderate to Severe Plaque Psoriasis
Overview
Protocol  I1F-MC-RHCR(a) A 24 Week Mult icenter, Randomized, Double Blind, Parallel Group 
Study  Com paring the Efficacy and Safet y of Ixekizum ab to Gusel kumab in Patients wi th 
Moderate to Severe Plaque Psoriasis has been amended.  The new protocol is indicated by  
[CONTACT_61504] ( b) and will be used to conduct the study  in place of any preceding version o f the 
protocol .
The overall changes and rationale for the changes m ade to thi s protocol  are described in the 
following table:
I1F-MC-RHCR(b) Clinical Protocol Page 85
LY2439821Amendment Summary for Protocol I1F-MC-RHCR Amendment ( b)
Section # and Name [CONTACT_23688]
5.1Overall Design Addedthe following clarification to “the other
appropriate means ”of patient blinding by [CONTACT_248196]:
“physical barrier means communicated to the 
sponsor for final approval.”Improve clarity 
5.2Number of Participants Rephrase d 1stsentence of the2ndparagraph and 
replace d“treatment with” with “expos ure to” in the 
last sentence of the 2ndparagraph.Improve clarity 
6.2 Exclusion Criteria Exclusion criteria # [15]
Rem ovedthe restriction of participat ion in any  
study investigating other IL -[ADDRESS_301765] in clinical trial settings will b e allowed 
as long as all other i nclusion/exclusion criteria are 
respected ; especially > 5 half -lives washout period 
before baseline visit (Week 0, Visit 2). As specified 
in Section 5.[ADDRESS_301766](s) will be limited to approximately 15% 
of the total patient population.
I1F-MC-RHCR(b) Clinical Protocol Page 86
LY2439821Section # and Name [CONTACT_23688]
6.2 Exclusion Criteria Exclusion criteria # [22]
Addedthe following clarifications:
“except for basal cell carcinoma, squamous cell 
carcinoma, skin Bowen’s disease or actinic 
keratosis that have been treated with no evidence of 
recurrence in the past [ADDRESS_301767] been removed .”This addition is to clarify that subjects with th e 
types of non- invasive malignancies and 
Non-Melanoma Skin Cancers (NMSC) , as 
described in the clarification , can be included  in 
this study , if they
 have been successfully treated 
with no evidence of recurrence .  This is similar to 
other biologicals psoriasis studies and aligned with 
both products labels . In Lilly ’s opi[INVESTIGATOR_3078] n, including 
such patients in this short study (24
 weeks of active 
treatment periods) will not pose an increased risk of 
such events since similar populations
 have 
previously participated in other biological psoriasis 
studies.
6.2.[ADDRESS_301768] from the description of 
exclusion criteria andeditorial change s. For content consistency as a result of changes made 
to Exclusion Criteria #[15] .  
7.8Concomitant Therapy Table RHCR.7.3
Drug Class “IL 17, IL -23p19  antagonists, other 
than the 2 products used as part of this protocol” :
Rem ovedIL-17and r eplace d“treatment with” with 
“exposure to” in the description of Condition for 
Use. For content consistency as a result of changes made 
to Exclusion Criteria #[15] and improve clarity.
I1F-MC-RHCR(b) Clinical Protocol Page 87
LY2439821Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Addit ions have been identified by  [CONTACT_58002] .
5.1. Overall Design
Unblinded Site Personnel are also responsible for maintaining the blind of the patient (e .g., by 
[CONTACT_3553] a blindfo ld or other appropriate physical barrier means communicated to the sponsor 
for final approval ).
5.2. Number of Participants
Patients wi th previ ous bi ologic use (note:  except concurrent or recent use of any bio logic agent 
< 5 half lives) will be canbeincluded in the study provi ded all inclusio n/exclusion criteria, 
including the washout period(s), as specified in (see Secti ons6.1 and 6.2).of this protocol  are 
respected .  Patients with previous treatm ent wi thexposure to another IL -[ADDRESS_301769](s) will be 
limited to approximately 15% of the total pat ient populat ion.
6.2. Exclusion Criteria
[15] Have previously co mpleted or withdrawn fro m this study , parti cipated in any o ther study  
with ixekizumab or guselkumab, have participated in any  study  invest igatingother IL [ADDRESS_301770] received treatment with ixekizumab.
[22] Have current or a history  of lymphoproliferat ive disease, or signs or symptoms of 
lymphoproliferat ive disease within 5 years o f baseline (Week 0, Visit 2); or have active or 
history  of malignant di sease wi thin 5 years of baseline (Week 0, Visit 2) ,except forbasal 
cell carcino ma, squamous cell carcino ma, skin Bowen’s disease or actinic keratoses that 
have been treated with no evidence of recurrence in the past [ADDRESS_301771] been removed .
(Note:  patients with history  of malignancy  with no evidence of recurrenc e or acti ve 
disease wi thin 5 years of baseline may participate in the study ).
6.2.1 Rationale for Exclusion of Certain Study Candidates
Exclusio n Cri teria [12] through [16] exclude pati ents who have pri or exposure to :guselkumab, 
or any  IL-23p19 antagonist ,or ixekizumab or any  IL [ADDRESS_301772] (note: see details in Sect ions 
6.2 and 5.2), or any  patients who arereceiving treatment or concomitant medicat ions that coul d 
have a negat ive impact on the safet y of patients enrolled or conf ound the resul ts of the study .
I1F-MC-RHCR(b) Clinical Protocol Page 88
LY24398217.8. Concomitant Therapy
Table RHCR.7.3. Concomitant Medications Permitted/Not Permitted in the Study and 
Conditions for Use
IL-17, IL -23p19 antago nists, other 
than the [ADDRESS_301773] never received ixekizumab or IL -23p19 
antagonists; or participated in any study investigating IL17, 
andIL-23p19 antagonists.  Patient with previous treatment
withexposure to another IL -[ADDRESS_301774](s) will be limited 
to approximately15% of the total patient population.
Leo Document ID = 3370197c-0e46-4820-9021-8de9b79bc46c
Approver:
Approval Date & Time: 07-Dec-2018 18:47:26 GMT
Signature [CONTACT_32869]: Approved
Approver:
Approval Date & Time: 07-Dec-2018 19:02:47 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]